UNIVERSITY of York

This is a repository copy of Dimer-induced signal propagation in SpoOA.

White Rose Research Online URL for this paper: http://eprints.whiterose.ac.uk/448/

# Article:

Muchova, K, Lewis, R J, Perecko, D et al. (5 more authors) (2004) Dimer-induced signal propagation in Spo0A. Molecular Microbiology. pp. 829-842. ISSN 0950-382X

https://doi.org/10.1111/j.1365-2958.2004.04171.x

# Reuse

Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item.

# Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.



eprints@whiterose.ac.uk https://eprints.whiterose.ac.uk/

# Dimer-induced signal propagation in Spo0A

# K. Muchová,<sup>1</sup> R. J. Lewis,<sup>2†</sup> D. Perečko,<sup>1</sup> J. A. Brannigan,<sup>2</sup> J. C. Ladds,<sup>2</sup> A. Leech,<sup>3</sup> A. J. Wilkinson<sup>2</sup> and I. Barák<sup>1\*</sup>

<sup>1</sup>Institute of Molecular Biology, Slovak Academy of Sciences, 845 51 Bratislava 45, Slovakia. <sup>2</sup>Structural Biology Laboratory, Department of Chemistry, and <sup>3</sup>Technology Facility, Department of Biology, University of York, Heslington, York YO10 5YW, UK.

### Summary

Spo0A, the response regulator protein controlling the initiation of sporulation in Bacillus, has two distinct domains, an N-terminal phosphoacceptor (or receiver) domain and a C-terminal DNA-binding (or effector) domain. The phosphoacceptor domain mediates dimerization of Spo0A on phosphorylation. A comparison of the crystal structures of phosphorylated and unphosphorylated response regulators suggests a mechanism of activation in which structural changes originating at the phosphorylatable aspartate extend to the  $\alpha_4\beta_5\alpha_5$  surface of the protein. In particular, the data show an important role in downstream signalling for a conserved aromatic residue (Phe-105 in Spo0A), the conformation of which alters upon phosphorylation. In this study, we have prepared a Phe-105 to Ala mutant to probe the contribution of this residue to Spo0A function. We have also made an alanine substitution of the neighbouring residue Tyr-104 that is absolutely conserved in the Spo0As of spore-forming Bacilli. The spo0A(Y104A) and spo0A(F105A) alleles severely impair sporulation in vivo. In vitro phosphorylation of the purified proteins by phosphoramidate is unaffected, but dimerization and DNA binding are abolished by the mutations. We have identified intragenic suppressor mutations of spo0A(F105A) and shown that these second-site mutations in the purified proteins restore phosphorylation-dependent dimer formation. Our data support a model in which dimerization and signal transduction between the two domains of Spo0A are mediated prin-

© 2004 Blackwell Publishing Ltd

cipally by the  $\alpha_4\beta_5\alpha_5$  signalling surface in the receiver domain.

### Introduction

Sporulation in Bacillus subtilis is controlled by an expanded two-component signal transduction system called a phosphorelay (Trach et al., 1991). Environmental signals trigger the autophosphorylation on histidine of up to five sensor kinases (Ireton et al., 1993; Jiang et al., 2000). The phosphoryl group is then transferred sequentially from the kinase to Spo0F, Spo0B and, finally, to the response regulator Spo0A. Spo0A consists of a receiver domain, which is phosphorylated on Asp-56 by the phosphorelay components, and an effector domain, which is capable of binding to specific DNA sequences, called 0A boxes, and regulating transcription. For the switch from stationary phase to sporulation to take place, a threshold concentration of phosphorylated Spo0A (Spo0A~P) has to be attained (Chung et al., 1994). The importance of Spo0A as an activator and a repressor of transcription of many stationary phase as well as sporulation-specific genes is emphasized by the finding that more than 500 transcripts in *B*. subtilis are dependent on Spo0A (Fawcett et al., 2000).

Spo0A dimerizes upon phosphorylation, with dimer formation mediated principally by the N-terminal receiver domain (Asayama et al., 1995; Lewis et al., 2002). The crystal structures of the receiver (N-Spo0A) and effector (C-Spo0A) domains of Spo0A from Bacillus stearothermophilus have been solved (Lewis et al., 2000a,b), the former in the phosphorylated form (Lewis et al., 1999). Recently, insight into the mode of DNA binding by Spo0A has emerged with the determination of the crystal structure of the effector domain of Spo0A in complex with a duplex oligonucleotide representing part of the abrB promoter (Zhao et al., 2002). Although the isolated effector domain is a monomer, in the structure of the DNA complex, C-Spo0A forms a dimer. It is also known that the isolated effector domains, created by genetic deletion or proteolysis, are capable of binding to DNA and altering the levels of transcription of Spo0A-controlled genes (Spiegelman et al., 1995). Unphosphorylated Spo0A does not bind to 0A boxes in vitro (Ladds et al., 2003), and thus cannot regulate transcription. Other experiments showed that the Spo0A effector domain alone is able to function as the transcription regulator in B. subtilis cells (Florek et al., 2002). It would appear that, in common with

Accepted 25 March, 2004. \*For correspondence. E-mail imrich.barak@savba.sk; Tel. (+421) 2 5930 7418; Fax (+421) 2 5930 7416. <sup>†</sup>Present address: Institute of Cell and Molecular Biosciences, Faculty of Medical Sciences, University of Newcastle, Newcastle upon Tyne NE2 4HH, UK.

other response regulators (Ellison and McCleary, 2000), the function of the Spo0A receiver domain is to inhibit the effector domain, and that phosphorylation serves to overcome this inhibition. What are unknown at present are (i) the nature of the intersubunit interactions in Spo0A dimers; (ii) the nature of the interdomain interactions responsible for inhibition in unphosphorylated Spo0A; and (iii) whether a common surface on the receiver domain is responsible for both sets of interactions.

In this study, we have prepared alanine substitutions of Tyr-104 and Phe-105 in order to investigate signalling between the N- and C-domains in Spo0A. Comparison of the crystal structure of N-Spo0A~P with structures of unphosphorylated response regulators suggested that the structural changes associated with phosphorylation of Spo0A are not extensive (Lewis et al., 1999). The most obvious change is a reorientation of the side-chain of Thr-84, which moves in the order of 5 Å so that its hydroxyl group makes a charge-dipole contact to an oxygen of the phosphoryl group. The repositioning of Thr-84 is accompanied by a structural rearrangement of the side-chain of Phe-105, which is redirected from an outward to an inward orientation with respect to the core of the receiver domain (Lewis et al., 1999). The available evidence from studies of other systems suggests that this 'aromatic switch' is a conserved aspect of signalling in response regulators (Birck et al., 1999; Cho et al., 2001; Lee et al., 2001; Park et al., 2002; Gardino et al., 2003; Hastings et al., 2003). To evaluate the contribution of Phe-105 to signalling in Spo0A directly, this residue was mutated to alanine. We also noted that the preceding residue, Tyr-104, which is on the surface of N-Spo0A~P, is invariant in Spo0A orthologues, although it is not conserved in the wider response regulator family. This suggests an important function for Tyr-104 that is confined to Spo0A and, accordingly, this amino acid residue was also substituted with alanine. We have analysed the effects of these mutations on SpoOA function in vivo and in vitro. These and other data are discussed in terms of a structural model for dimer formation and signal propagation.

## Results

# Alanine substitution of Tyr-104 and Phe-105

To evaluate the functional importance of Tyr-104 and Phe-105, we have introduced alanine substitutions at these positions by site-directed mutagenesis. The mutated *spo0A* alleles were introduced into the chromosome of wild-type *B. subtilis* PY79 by single cross-over recombination, creating the strains IB658 and IB659 respectively (Table 1). The two mutations have severe effects on sporulation, similar to that in strain IB220 in which the *spo0A* gene is disrupted (Table 2). Relative to the wildtype strain, the sporulation efficiency of the mutants is reduced  $10^4$ - to  $10^5$ -fold. To investigate the mutations further, recombinant Spo0A(Y104A) and Spo0A(F105A) were overproduced in *Escherichia coli* and purified to homogeneity for biophysical and biochemical assays.

# Spo0A(Y104A) and Spo0A(F105A) fail to form dimers

Size exclusion chromatography on a Superdex 75 HR 10/ 30 gel filtration column was used to determine the oligomeric state of Spo0A(Y104A) and Spo0A(F105A). Both mutant proteins eluted from this column in the same volume as wild-type Spo0A, indicating that they are mono-(Fig. 1A-C and Table 3). To examine the mers phosphorylated forms, the three proteins were treated with 50 mM phosphoramidate. The elution volume of phosphoramidate-treated wild-type Spo0A decreased from 10.7 ml to 9.3 ml, indicating an increase in mass, which we have shown previously to result from dimer formation (Lewis et al., 2002). The elution volumes of the two mutant proteins showed a much smaller reduction, suggesting that these proteins are principally monomers. After treatment of all three samples with Spo0E, the Spo0A phosphate-specific phosphatase, the elution volumes were restored to those before treatment with phosphoramidate (data not shown).

Sedimentation velocity analytical ultracentrifugation (AUC) experiments were performed on purified preparations of wild-type Spo0A, Spo0A(Y104A) and Spo0A(F105A). The molecular weights of the three proteins were observed to be 27.2, 26.7 and 25.3 kDa, respectively, confirming that all three proteins are monomers (Table 3). Subsequent AUC analysis of the phosphoramidate-treated proteins gave observed molecular weights of 28.4 and 27.3 kDa for Spo0A(Y104A)~P and Spo0A(F105A)~P respectively. Two species with molecular weights of 25.3 and 48.4 kDa were observed for wildtype Spo0A (Table 3). The data suggest that a significant proportion of the wild-type Spo0A sample forms dimers upon exposure to phosphoramidate. In contrast, the mutant proteins remain as monomers. The absence of dimers of the Ala-104 and Ala-105 mutants may be caused by their failure to (i) be significantly phosphorylated in the presence of phosphoramidate or (ii) assemble into dimers after phosphorylation.

# Spo0A(Y104A) and Spo0A(F105A) are not impaired in phosphorylation

To establish whether Spo0A(Y104A) and Spo0A(F105A) are phosphorylated by phosphoramidate, we used a nondenaturing polyacrylamide gel electrophoresis (PAGE) assay. The phosphorylated and unphosphorylated forms of Spo0A have very low mobilities in conventional polyTable 1. Bacterial strains, plasmids and oligonucleotides used in this study.

E. coli       endA1 hsdF17 supE44 thi-1 recA*       Backma et al. (1976)         MM294       endA1 hsdF17 supE44 thi-1 recA*       Yanish-Perron et al. (1986)         M110       rpsL thr leu thi-1 lacY galK galT ara       Yanish-Perron et al. (1986)         M120       http://mail.com.path.et/al.(202M)15]       Novagen         BL21(DE3)       http://mail.com.path.et/al.(202M)15]       Novagen         B220       sp00A:kan       Schmeisser et al. (2000)         B658       PY73:::pBG15YA, Spo       This work         B669       Spo0' mutant after treatment of IB659 with EMS       This work         B6686       Spo0' mutant after treatment of IB659 with EMS       This work         B6690       Spo0' mutant after treatment of IB659 with EMS       This work         B6690       Spo0' mutant after treatment of IB659 with EMS       This work         B6690       Spo0' mutant after treatment of IB659 with EMS       This work         B615       Amg', Cm', pGEM-32(+)-cat-1, promoterless spo0A gene       Youngman (1990)         P12780:PL74       Same as pEG15 with mutation Spo0AY104A       This work         P12780:PL74       Same as pEG15 with mutation Spo0AY104A       This work         P12780:PL74       Km', lac, T 2 promoter, spo0AY104A       This work         P1270AF       Km', lac, T 2 promoter,	Strain or name	Genotype, phenotype, sequence and relevant characteristics	Source or reference
MM294     endA1 hsdR17 supE44 thi-1 recA'     Backman et al. (1976) InAl tsx dam dom supE44 (ilcs-proAB)       Vanish-Perron et al. (1985) InAl tsx dam dom supE44 (ilcs-proAB)     Vanish-Perron et al. (1986)       BL21(DE3)     hssUS gal (\lambda classes)       BL21(DE3)     hssUS gal (\lambda classes)       PY79     Prototroph     Youngman (1990)       BS20     sp004:kan     Schmäbser et al. (2000)       IB658     PY79::::::::::::::::::::::::::::::::::::	E. coli		
JM110 rest. thr lear this lacY galK galT ara (and shares) (1985) icon Liss dam dam supple 44 (liac-proAB) F (lraD36 proAB' lacF lacZM15) BL21(DE3) hsdS gal (Att8857 ind1 Sam7 nin5 lacUV5-T7 gene1) Novagen B subtilis B subtilis B volume and the supple and	MM294	endA1 hsdR17 supE44 thi-1 recA*	Backman <i>et al.</i> (1976)
bit A iss dam dom supE44 (ilex-proAB)       Fr (irabB proAB' ise/i haz2M15)         BL21(DES)       hsdS gal (\label{ac2M15})         B. subtilis       Youngman (1990)         Pr/39       Prototroph       Youngman (1990)         BES8       sp04::kan       Schmeisser et al. (2000)         BES8       PY79::pBG15FA, Spo <sup>-</sup> This work         BE685       Sp0A::kan       Schmeisser et al. (2000)         BE685       Sp0A:ToSAT94M       This work         BE686       Sp0A+105A194M       This work         B667       Spo0A+105A194M       This work         B668       Spo0A+105A194M       This work         B668       Spo0A+105A194M       This work         B669       Spo <sup>-</sup> mutant after treatment of IB659 with EMS       This work         Spo0A+105A020R       Plasmids       This work         Plasmids       Spo0A+105A020R       This work         PEG15       Amp', Cm', pGEM-32((+)-cat-1, promoterless <i>spo0A</i> gene       Youngman (1990)         PGG15A       Same as pBG15 with mutation Spo0A/104A       This work         PET0ASP1       Km', <i>laci</i> , T7 promoter, <i>spo0A/105A</i> This work         PET0ASP1       Km', <i>laci</i> , T7 promoter, <i>spo0A/105A</i> This work         PET0ASP1       Km',	JM110	rpsL thr leu thi-1 lacY galK galT ara	Yanish-Perron et al. (1985)
B210(DS)       hs/dS gal (Adt8657 ind1 Sam7 nin5 lac/U/S-T7 gene1)       Novagen         B_subfile       Youngman (1990)         B_subfile       Youngman (1990)         B220       sp0Ak:kan       Schmeisser et al (2000)         B658       PY78:pBG15FA, Spo       This work         B659       PY78:pBG15FA, Spo       This work         B6685       Spo 'mutant after treatment of IB659 with EMS       This work         Sp0AF105AQ12R       SpoAF105AQ12R       SpoAF105AQ12R         B6866       Spo 'mutant after treatment of IB659 with EMS       This work         Sp0AF105AQ12R       Sp0AF105AQ12R       Sp0AF105AQ12R         B6800       Sp0 'mutant after treatment of IB659 with EMS       This work         Sp0AF105AQ12R       Sp0AF105AQ12R       Sp0AF105AQ12R         B690       Sp0' mutant after treatment of IB659 with EMS       This work         Sp0AF105AQ08R       This work       Sp0AF105AQ20R         Plasmids       This work       Sp0AF105AQ20R       This work         B6157A       Same as pBG15 with mutation Sp0AF105A       This work       Sp0AF105AQ20R         P128b(-1)       Km', lac! T7 promoter, sp0AF105A       This work       Sp0AF105AQ20R         P1278b(-1)       Km', lac! T7 promoter, sp0AF105A       This work       <		tonA tsx dam dcm supE44 $\wedge$ (lac-proAB)	
BL21(DE3) hadS gal (Actis857 ind1 Sam7 inf JacUV5-T7 gene1) Novagen <i>B</i> . subtilis <i>B</i> . <i>B</i> . subtilis		F' [traD36 proAB <sup>+</sup> lacl <sup>q</sup> lacZ/M15]	
Bisubility     House part (Marco and Marco and Mar	BI 21(DE3)	hsdS gal () clts857 ind1 Sam7 nin5 lacl IV5-T7 gene1)	Novagen
Description     Youngman (1990)       IB220     spo0A:kan     Schmeisser et al. (2000)       IB658     PY79::::::::::::::::::::::::::::::::::::	B subtilis	noue gar (nonseer man cann mine lace ve th gener)	Novagen
F173       F1000001       F0000000         B6220       sp0000000       Sp0000000       Schmeisser et al. (2000)         B658       PY79:::pBG15FA, Sp0*       This work         B659       PY79:::pBG15FA, Sp0*       This work         B659       PY79:::pBG15FA, Sp0*       This work         B685       Sp0* mutant after treatment of IB659 with EMS       This work         Sp00AF105A704M       Sp00AF105A704M       This work         B686       Sp0* mutant after treatment of IB659 with EMS       This work         Sp00AF105A020R       Sp0* mutant after treatment of IB659 with EMS       This work         B687       Sp0* mutant after treatment of IB659 with EMS       This work         Sp00AF105A020R       Sp0* mutant after treatment of IB659 with EMS       This work         PB6157A       Sp0* mutant after treatment of IB659 with EMS       This work         PB6157A       Same as pB615 with mutation Sp00AF105A       This work         PB6157A       Same as pB615 with mutation Sp00AF105A       This work         PET26b(+)       Km*, <i>lact</i> , T7 promoter       Novagen       Novagen         PET0AF       Km*, <i>lact</i> , T7 promoter, <i>sp00AF105A194M</i> This work       PET0AFF         PET0ASF1       Km*, <i>lact</i> , T7 promoter, <i>sp00AF105A194M</i> This work		Prototroph	Youngman (1000)
IB220     Sp00rAal     Schmisser et al. (2000)       IB658     PY79::pBG15VA, Spo <sup>-</sup> This work       IB659     PY79::pBG15FA, Spo <sup>-</sup> This work       IB658     Spo <sup>0</sup> mutant after treatment of IB659 with EMS     This work       IB686     Spo <sup>0</sup> mutant after treatment of IB659 with EMS     This work       IB687     Spo <sup>0</sup> mutant after treatment of IB659 with EMS     This work       IB687     Spo <sup>0</sup> mutant after treatment of IB659 with EMS     This work       IB680     Spo <sup>0</sup> mutant after treatment of IB659 with EMS     This work       IB680     Spo <sup>0</sup> mutant after treatment of IB659 with EMS     This work       IB690     Spo <sup>0</sup> mutant after treatment of IB659 with EMS     This work       IB691     Amp <sup>1</sup> , Cm <sup>1</sup> , pGEM-32t(+)-cat-1, promoterless spo0A gene     Youngman (1990)       PG615     Amp <sup>1</sup> , Cm <sup>1</sup> , pGEM-32t(+)-cat-1, promoterless spo0A gene     Youngman (1990)       PG6157A     Same as pBG15 with mutation Spo0AF105A     This work       PG70AF     Km <sup>1</sup> , lac, T7 promoter     Novagen     This work       PET0AF     Km <sup>1</sup> , lac, T7 promoter, spo0AF105A0121R     This work       PET0ASF2     Km <sup>1</sup> , lac, T7 promoter, spo0AF105A0121R     This work       PET0ASF4     Km <sup>1</sup> , lac, T7 promoter, spo0AF105A0128     This work       PET0ASF4     Km <sup>1</sup> , lac, T7 promoter, spo0AF105A0128     This work	I 175	aneQAukan	Sebmologer et al. (2000)
IB056     P17.9:JpDG157A, Sp0     This work       IB659     P17.9:JpDG157A, Sp0     This work       IB685     Sp0* mutan after treatment of IB659 with EMS     This work       IB686     Sp0* mutan after treatment of IB659 with EMS     This work       IB687     Sp0* mutan after treatment of IB659 with EMS     This work       IB687     Sp0* mutan tafter treatment of IB659 with EMS     This work       IB680     Sp0* mutan tafter treatment of IB659 with EMS     This work       IB680     Sp0* mutan tafter treatment of IB659 with EMS     This work       IB680     Sp0* mutan tafter treatment of IB659 with EMS     This work       IB680     Sp0* mutan tafter treatment of IB659 with EMS     This work       IB680     Sp0* mutant after treatment of IB659 with EMS     This work       IB6815     Amp', Cm', pGEM-3zf(+)-cat-1, promoterless <i>sp00A</i> gene     Youngman (1990)       pB6155     Amp', Cm', act, T7 promoter     Novagen       pET045     Same as pBG15 with mutation Sp00AF105A     This work       pET045     Km', <i>lact</i> , T7 promoter, <i>sp00AF105A</i> This work       pET045     Km', <i>lact</i> , T7 promoter, <i>sp00AF105AQ90P</i> This work       pET045     Km', <i>lact</i> , T7 promoter, <i>sp00AF105AQ90P</i> This work       pET04574     Km', <i>lact</i> , T7 promoter, <i>sp00AF105AQ90P</i> This work       pET04574	ID220	SPUUAKAII	Schineisser et al. (2000)
H5659     PY 9::ptG15PA, Sp0     Inits work       B6855     Sp0 <sup>1</sup> mutant after treatment of IB659 with EMS     This work       B686     Sp0 <sup>1</sup> mutant after treatment of IB659 with EMS     This work       B687     Sp0 <sup>1</sup> mutant after treatment of IB659 with EMS     This work       B686     Sp0 <sup>1</sup> mutant after treatment of IB659 with EMS     This work       B687     Sp0 <sup>1</sup> mutant after treatment of IB659 with EMS     This work       B680     Sp0 <sup>1</sup> mutant after treatment of IB659 with EMS     This work       B687     Sp0 <sup>0</sup> mutant after treatment of IB659 with EMS     This work       B680     Sp0 <sup>1</sup> mutant after treatment of IB659 with EMS     This work       B615     Amp', Cm', pGEM-3zf(+)-cat-1, promoterless <i>sp00A</i> gene     Yourgman (1990)       PB6157VA     Same as pBG15 with mutation Sp00AF105A     This work       PB6157VA     Same as pBG15 with mutation Sp00AF105A     This work       PET04SP     Km', <i>lact</i> T7 promoter, <i>sp00AF105A</i> This work       PET04SF1     Km', <i>lact</i> T7 promoter, <i>sp00AF105A0121R</i> This work       PET0ASF2     Km', <i>lact</i> T7 promoter, <i>sp00AF105A02121R</i> This work       PET0ASF3     Km', <i>lact</i> T7 promoter, <i>sp00AF105A02121R</i> This work       PET0ASF4     Km', <i>lact</i> T7 promoter, <i>sp00AF105A02121R</i> This work       PET0ASF3     Km', <i>lact</i> T7 promoter, <i>sp00AF105A020R</i>	IB058		
IB685     Spo Mutant after treatment of IB659 with EMS     Inits work       Spo AF105AT94M     IB686     Spo' mutant after treatment of IB659 with EMS     This work       IB687     Spo' mutant after treatment of IB659 with EMS     This work       Spo' mutant after treatment of IB659 with EMS     This work       B687     Spo' mutant after treatment of IB659 with EMS     This work       Spo' mutant after treatment of IB659 with EMS     This work       B680     Spo' mutant after treatment of IB659 with EMS     This work       B6815     Amp', Cm', pGEM-3zf(-)-cat-1, promoterless <i>spo0A</i> gene     Youngman (1990)       PB6157A     Same as pB615 with mutation Spo0AF105A     This work       DF126b(+)     Km', <i>laci</i> , T7 promoter     Novagen       DF10AF     Km', <i>laci</i> , T7 promoter, <i>spo0AF105A</i> This work       DF10ASF1     Km', <i>laci</i> , T7 promoter, <i>spo0AF105AQ90R</i> This work       DF10ASF2     Km', <i>laci</i> , T7 promoter, <i>spo0AF105AQ90R</i> This work       DF10ASF3     Km', <i>laci</i> , T7 promoter, <i>spo0AF105AQ90R</i> This work       DF10ASF4     Km', <i>laci</i> , T7 promoter, <i>spo0AF105AQ90R</i> This work       DF10ASF4     Km', <i>laci</i> , T7 promoter, <i>spo0AF105AQ90R</i> This work       NUT7     S'-TGAGAATAAGGCGAGACGCGCCT-3'     Introduces Tr-104Ala mutation       MUT7     S'-CGAGGAAACAGCGTAGAGACGCGCCT-3'     Introduces Phe-1	IB659	PY79::pBG15FA, Spo	This work
IB686     Spo' mutant after treatment of IB659 with EMS     This work       Spo0AF105A0121R     This work       IB687     Spo' mutant after treatment of IB659 with EMS     This work       B680     Spo' mutant after treatment of IB659 with EMS     This work       B680     Spo' mutant after treatment of IB659 with EMS     This work       B680     Spo' mutant after treatment of IB659 with EMS     This work       B680     Spo' mutant after treatment of IB659 with EMS     This work       B680     Spo' mutant after treatment of IB659 with EMS     This work       B68157     Amp', Cm', pGEM-3zf(+)-cat-1, promoterless <i>spo0A</i> gene     Youngman (1990)       pB6157     Same as pB615 with mutation Spo0AF105A     This work       pE10457     Same as pB615 with mutation Spo0AF105A     This work       pE10457     Km', <i>lact</i> , T7 promoter, <i>spo0AF105A</i> This work       pE10457     Km', <i>lact</i> , T7 promoter, <i>spo0AF105A794M</i> This work       pE104572     Km', <i>lact</i> , T7 promoter, <i>spo0AF105A02121R</i> This work       pE104573     Km', <i>lact</i> , T7 promoter, <i>spo0AF105A02121R</i> This work       pE104574     Km', <i>lact</i> , T7 promoter, <i>spo0AF105A020R</i> This work       pE104575     Km', <i>lact</i> , T7 promoter, <i>spo0AF105A020R</i> This work       pE104574     Km', <i>lact</i> , T7 promoter, <i>spo0AF105A02121R</i> This work <t< td=""><td>IB685</td><td>Spo<sup>+</sup> mutant after treatment of IB659 with EMS Spo0AF105AT94M</td><td>This work</td></t<>	IB685	Spo <sup>+</sup> mutant after treatment of IB659 with EMS Spo0AF105AT94M	This work
IB687     Sport mutant after treatment of IB659 with EMS     This work       Sp00AF105AH162R     Sp00AF105AQ90R     This work       Plasmids     mpf, Cm', pGEM-3zf(+)-cat-1, promoterless <i>sp00A</i> gene     Youngman (1990)       pBG15     Amp', Cm', pGEM-3zf(+)-cat-1, promoterless <i>sp00A</i> gene     Youngman (1990)       pBG155A     Same as pBG15 with mutation Sp00AY104A     This work       pE1045FA     Same as pBG15 with mutation Sp00AY104A     This work       pE1054     Km', <i>lacl</i> , T7 promoter, <i>sp00AF105A</i> This work       pE1045FA     Km', <i>lacl</i> , T7 promoter, <i>sp00AF105A</i> This work       pE1045FA     Km', <i>lacl</i> , T7 promoter, <i>sp00AF105A</i> This work       pE1045F2     Km', <i>lacl</i> , T7 promoter, <i>sp00AF105A</i> This work       pE1045F2     Km', <i>lacl</i> , T7 promoter, <i>sp00AF105AQ90R</i> This work       pE1045F2     Km', <i>lacl</i> , T7 promoter, <i>sp00AF105AQ90R</i> This work       pE1045F3     Km', <i>lacl</i> , T7 promoter, <i>sp00AF105AQ90R</i> This work       pE1045F3     Km', <i>lacl</i> , T7 promoter, <i>sp00AF105AQ90R</i> This work       pE1045F3     Km', <i>lacl</i> , T7 promoter, <i>sp00AF105AQ90R</i> This work       pE1045F3     Km', <i>lacl</i> , T7 promoter, <i>sp00AF105AQ90R</i> This work       pE1045F3     Km', <i>lacl</i> , T7 promoter, <i>sp00AF105AQ4102</i> This work       pE1045F4     S'-GAGAATAAAGGCGTAGGACGCGCCCT3'     In	IB686	Spo <sup>+</sup> mutant after treatment of IB659 with EMS Spo0AF105AQ121R	This work
Sp00AF105AH162R         IB690       Sp0'mutant after treatment of IB659 with EMS       This work         Plasmids       pBG15       Amp', Cm', pGEM-3zf(+)-cat-1, promoterless <i>sp00A</i> gene       Youngman (1990)         PBG15       Amp', Cm', pGEM-3zf(+)-cat-1, promoterless <i>sp00A</i> gene       Youngman (1990)         PBG15YA       Same as pBG15 with mutation Sp00AY104A       This work         pBG15FA       Same as pBG15 with mutation Sp00AY104A       This work         pET26b(+)       Km', <i>laci</i> , T7 promoter, <i>sp00AY104A</i> This work         pET0AY       Km', <i>laci</i> , T7 promoter, <i>sp00AF105A</i> This work         pET0ASF1       Km', <i>laci</i> , T7 promoter, <i>sp00AF105AT94M</i> This work         pET0ASF2       Km', <i>laci</i> , T7 promoter, <i>sp00AF105AQ90R</i> This work         pET0ASF2       Km', <i>laci</i> , T7 promoter, <i>sp00AF105AQ90R</i> This work         pET0ASF4       Km', <i>laci</i> , T7 promoter, <i>sp00AF105AQ90R</i> This work         pET0ASF4       Km', <i>laci</i> , T7 promoter, <i>sp00AF105AQ90R</i> This work         pET0ASF4       Km', <i>laci</i> , T7 promoter, <i>sp00AF105AQ90R</i> This work         Qigonucleotides       5'-TGAGAATAAGGGAAGGCGACGCGCCT-3'       This work         R1       5'-GGAGAATAAGGGAAGGCGAAGGCGCCC-3'       This work         WUT7       5'-GCGGGAACCCCAGGAGACGCGACGCCC-3' <td>IB687</td> <td>Spo<sup>+</sup> mutant after treatment of IB659 with EMS</td> <td>This work</td>	IB687	Spo <sup>+</sup> mutant after treatment of IB659 with EMS	This work
IB690     Spo <sup>*</sup> mutant after treatment of IB659 with EMS     This work       Spo <sup>*</sup> mutant after treatment of IB659 with EMS     This work       Spo <sup>*</sup> mutant after treatment of IB659 with EMS     This work       Spo <sup>*</sup> mutant after treatment of IB659 with EMS     This work       PBG15     Amp', Cm', pGEM-3zf(+)-cat-1, promoterless <i>spo0A</i> gene     Youngman (1990)       pBG1557A     Same as pBG15 with mutation Spo0AF105A     This work       pE10457A     Same as pBG15 with mutation Spo0AF105A     This work       pET045     Km', <i>laci</i> , T7 promoter, <i>spo0AF105A</i> This work       pET045     Km', <i>laci</i> , T7 promoter, <i>spo0AF105A</i> This work       pET0457     Km', <i>laci</i> , T7 promoter, <i>spo0AF105A090R</i> This work       pET0457     Km', <i>laci</i> , T7 promoter, <i>spo0AF105A090R</i> This work       pET04573     Km', <i>laci</i> , T7 promoter, <i>spo0AF105A090R</i> This work       pET04574     Km', <i>laci</i> , T7 promoter, <i>sp00AF105A090R</i> This work       pET04573     Km', <i>laci</i> , T7 promoter, <i>sp00AF105A090R</i> This work       pET04574     Km', <i>laci</i> , T7 promoter, <i>sp00AF105A090R</i> This work       pET04574     Km', <i>laci</i> , T7 promoter, <i>sp00AF105A090R</i> This work       pET04574     Km', <i>laci</i> , T7 promoter, <i>sp00AF105A090R</i> This work       pET04574     Km', <i>laci</i> , T7 promoter, <i>sp00AF105A0400R</i> This work		Spo0AF105AH162B	
Sp00AF105AQ90R         Plasmids         PBG15       Amp', Cm', pGEM-3zf(+)-cat-1, promoterless sp00A gene       Youngman (1990)         pBG155XA       Same as pBG15 with mutation Sp00AY104A       This work         pBG15FA       Same as pBG15 with mutation Sp00AY105A       This work         pBG15FA       Same as pBG15 with mutation Sp00AF105A       This work         pBG15FA       Same as pBG15 with mutation Sp00AF105A       This work         pBG15A       Km', lact, T7 promoter, sp00AF105A       This work         pET0AF       Km', lact, T7 promoter, sp00AF105A0121R       This work         pET0ASF2       Km', lact, T7 promoter, sp00AF105A0121R       This work         pET0ASF4       Km', lact, T7 promoter, sp00AF105A090R       This work         pET0ASF4       Km', lact, T7 promoter, sp00AF105A090R       This work         pET0ASF4       Km', lact, T7 promoter, sp00AF105A0121R       This work         pET0ASF4       Km', lact, T7 promoter, sp00AF105A0409R       This work         pET0ASF4       Km', lact, T7 promoter, sp00AF105A0121R       This work         pET0ASF4       S'-TGAGAATAACGCGTAGGCGCCCT-3'       This work         NUT7       S'-GCAGAATAACGCTACGGAGCGCCCC3'       His work         R4       S'-GCTCGGTACCCGGACACACC-3'       S'-GGAGAAACAGCTATGAC-3'	IB690	Spo <sup>+</sup> mutant after treatment of IB659 with EMS	This work
Plasmids       pBG15       Amp', Cm', pGEM-3zf(+)-cat-1, promoterless <i>spo0A</i> gene       Youngman (1990)         pBG155A       Same as pBG15 with mutation Spo0AY104A       This work         pBG15FA       Same as pBG15 with mutation Spo0AF105A       This work         pET26b(+)       Km', <i>lact</i> , T7 promoter       Novagen         pET0AY       Km', <i>lact</i> , T7 promoter, <i>spo0AF105A</i> This work         pET0AF       Km', <i>lact</i> , T7 promoter, <i>spo0AF105AT94M</i> This work         pET0ASF1       Km', <i>lact</i> , T7 promoter, <i>spo0AF105AO121R</i> This work         pET0ASF2       Km', <i>lact</i> , T7 promoter, <i>spo0AF105AO121R</i> This work         pET0ASF3       Km', <i>lact</i> , T7 promoter, <i>spo0AF105AO121R</i> This work         pET0ASF4       Km', <i>lact</i> , T7 promoter, <i>spo0AF105AO121R</i> This work         pET0ASF3       Km', <i>lact</i> , T7 promoter, <i>spo0AF105AO121R</i> This work         pET0ASF4       Km', <i>lact</i> , T7 promoter, <i>spo0AF105AO121R</i> This work         pET0ASF4       Km', <i>lact</i> , T7 promoter, <i>spo0AF105AO121R</i> This work         pET0ASF4       Km', <i>lact</i> , T7 promoter, <i>spo0AF105AO121R</i> This work         pET0ASF4       Km', <i>lact</i> , T7 promoter, <i>spo0AF105AO121R</i> This work         pET0ASF4       Km', <i>lact</i> , T7 promoter, <i>spo0AF105AO121R</i> This work      <		Spo0AE105AQ90B	
DBG15Amp', Cm', pGEM-3zf(+)-cat-1, promoterless spo0A geneYoungman (1990)pBG155Same as pBG15 with mutation Spo0AY104AThis workpBG15FASame as pBG15 with mutation Spo0AY104AThis workpBG15FASame as pBG15 with mutation Spo0AY105AThis workpBG15FASame as pBG15 with mutation Spo0AY104ANovagenpET26b(+)Km', lacl; T7 promoterNovagenpET0AYKm', lacl; T7 promoter, spo0AF105AThis workpET0ASF1Km', lacl; T7 promoter, spo0AF105AT94MThis workpET0ASF2Km', lacl; T7 promoter, spo0AF105AO121RThis workpET0ASF3Km', lacl; T7 promoter, spo0AF105AO121RThis workpET0ASF4Km', lacl; T7 promoter, spo0AF105AU12RThis workpET0ASF4Km', lacl; T7 promoter, spo0AF105AU12RThis workOligonucleotidesS'-TGAGAATAAAGGCGGACCGCGCCT-3'This workR15'-TGAGAATAAAGGCGGACGCGCCCT-3'introduces Phe-105Ala mutationMUT7S'-GCTCGGTACCCGGAGACCC-3'Eliminates BamHI site of pBG15M44S'-GTTTTCCCAGTCACGAC-3'Introduces Ndel siteC0AS'-ATAAGCTCAAGCTTAAGAAGCCTTATGCTCTAACCT-3'Introduces Ndel siteC0AS'-ATAAGCTCAAGCTTAAGAAGCCTTATGCTCTAACCT-3'Introduces Ndel siteABRBDTS'-GAGATTTCCTTAGATAATGACGAAAATTCGACAAAATCC-3'ABRBBOTATHESGGS'-ATATATAGGAATATTAA-3'ATHESGGATATATAGGAATATTAA-3'	Plasmids		
DecisionThis with mutation Spo0Ar104AThis workpBG15YASame as pBG15 with mutation Spo0Ar105AThis workpBG15FASame as pBG15 with mutation Spo0Ar105AThis workpET26b(+)Km', lac, T7 promoter, spo0Ar105ANovagenpET0AYKm', lac, T7 promoter, spo0Ar105AThis workpET0AFKm', lac, T7 promoter, spo0Ar105AQ121RThis workpET0ASF2Km', lac, T7 promoter, spo0Ar105AQ90RThis workpET0ASF3Km', lac, T7 promoter, spo0Ar105AQ90RThis workpET0ASF4Km', lac, T7 promoter, sp00Ar105AQ90RThis workpET0ASF5Km', lac, T7 promoter, sp00Ar105AQ90RThis workpET0ASF4Km', lac, T7 promoter, sp00Ar105AQ90RThis workpET0ASF4Km', lac, T7 promoter, sp00Ar105AQ90RThis workpET0ASF4S'-TGAGAATAAGCGGGACGCGCCT-3'This workpET0ASF4S'-TGAGAATAAGCGTAGGACGCGCCCT-3'This workNUT7S'-GGAGGAACACCATGGACAGCAGCCCC-3'This of the optical mutationMUT7S'-GGAGGAACACCATTAGAGAACCC-3'This of some same same same same same same same sa	nBG15	Amp <sup>r</sup> Cm <sup>r</sup> pGEM-3zf(+)-cat-1 promoterless spo0A gene	Youngman (1990)
DBG157A       Same as pBG15 with mutation Sp00AF105A       This work         pET26b(+)       Km', lacl; T7 promoter, sp00AF105A       This work         pET0AY       Km', lacl; T7 promoter, sp00AF105A       This work         pET0AF       Km', lacl; T7 promoter, sp00AF105A       This work         pET0AF       Km', lacl; T7 promoter, sp00AF105A1794M       This work         pET0ASF1       Km', lacl; T7 promoter, sp00AF105A0121R       This work         pET0ASF2       Km', lacl; T7 promoter, sp00AF105A0121R       This work         pET0ASF3       Km', lacl; T7 promoter, sp00AF105A0121R       This work         pET0ASF4       Km', lacl; T7 promoter, sp00AF105A0121R       This work         pET0ASF3       Km', lacl; T7 promoter, sp00AF105A090R       This work         pET0ASF4       Km', lacl; T7 promoter, sp00AF105A0400R       This work         PE10ASF4       Km', lacl; T7 promoter, sp00AF105A0208R       This work         PE10ASF4       Km', lacl; T7 promoter, sp00AF105A0208R       This work         PE10ASF4       S'-GTGAGACACGCGGCCCC3       This work	nBG15VA	Same as nBG15 with mutation Spo0AV10/A	This work
Detroval     Statle as points with initiation option in total     This work       pET26b(+)     Km', <i>lact</i> ; T7 promoter, <i>spo0AF105A</i> This work       pET0AF     Km', <i>lact</i> ; T7 promoter, <i>spo0AF105A</i> This work       pET0AF     Km', <i>lact</i> ; T7 promoter, <i>spo0AF105A</i> This work       pET0ASF1     Km', <i>lact</i> ; T7 promoter, <i>spo0AF105AQ121R</i> This work       pET0ASF2     Km', <i>lact</i> ; T7 promoter, <i>spo0AF105AQ121R</i> This work       pET0ASF3     Km', <i>lact</i> ; T7 promoter, <i>spo0AF105AQ90R</i> This work       pET0ASF4     Km', <i>lact</i> ; T7 promoter, <i>spo0AF105AQ90R</i> This work       pET0ASF4     Km', <i>lact</i> ; T7 promoter, <i>spo0AF105AQ90R</i> This work       Qligonucleotides     This work     This work       R1     5'-TGAGAATAAAGGCGGAGCGCGCCT-3'     This work       NUT7     5'-GCTCGGTACCCGGAGACGCGCCCT-3'     This work       MUT7     5'-GCTCGGTACCCGGAGACGC-3'     This       M4     5'-GCTCGGTACCCGGAGACC-3'     This       NOA     5'-GGAGGAAGACATATGGAGAAAATTAAAGTTTGTGT-3'     This work       Introduces Nucles Nucleis     This     This       C0A     5'-GGAGGAAGACATATGGAGAAAATTAAAGTTTGTGT-3'     This       Introduces Nucleis     This     This       R0A     5'-GGAGGAAGACATATGGAGAACACTATGCTCTAACCT-3'     This       MDA     5'-GGAGGAAGACAT	pBG15EA	Same as pBG15 with mutation Sp00AT104A	This work
pE1200(+)       NIN, lack, 17 promoter, sp00AF105A       This work         pET0AF       Km', lack, T7 promoter, sp00AF105A       This work         pET0ASF1       Km', lack, T7 promoter, sp00AF105A0       This work         pET0ASF2       Km', lack, T7 promoter, sp00AF105A0121R       This work         pET0ASF3       Km', lack, T7 promoter, sp00AF105A0121R       This work         pET0ASF3       Km', lack, T7 promoter, sp00AF105A0121R       This work         pET0ASF4       Km', lack, T7 promoter, sp00AF105A0121R       This work         pET0ASF3       Km', lack, T7 promoter, sp00AF105A0121R       This work         pET0ASF4       Km', lack, T7 promoter, sp00AF105A0121R       This work         pET0ASF4       Km', lack, T7 promoter, sp00AF105A0121R       This work         pET0ASF4       Km', lack, T7 promoter, sp00AF105AH162R       This work         PE10ASF4       Km', lack, T7 promoter, sp00AF105AH162R       This work         Oligonucleotides       This work       This work         R1       S'-TGAGAATAAGCGTAGGACGCGCCCT-3'       This work         NUT7       S'-GCTCGGTACCCGGAGACTC-3'       Fortinduces Phe-105Ala mutation         MUT7       S'-GGAGAACACGTATGGACGAC-3'       Fortinduces Almental site of pBG15         M4       S'-GGAGAACACACGTATGGACAC-3'       Fortintorduces Almental s			Nevegee
pETDAY       N/II, <i>laci</i> , 17 promoter, <i>spo0AF105A</i> This work         pETOAF       Km', <i>laci</i> , 17 promoter, <i>spo0AF105AT94M</i> This work         pETOASF1       Km', <i>laci</i> , 17 promoter, <i>spo0AF105AQ121R</i> This work         pETOASF2       Km', <i>laci</i> , 17 promoter, <i>spo0AF105AQ90R</i> This work         pETOASF3       Km', <i>laci</i> , 17 promoter, <i>spo0AF105AQ90R</i> This work         pETOASF4       Km', <i>laci</i> , 17 promoter, <i>spo0AF105AQ90R</i> This work         Qligonucleotides       Tris work       This work         R1       5'-TGAGAATAAGGCGGAGCGGCCCT-3'       introduces Tyr-104Ala mutation         R2       5'-TGAGAATACGCGTAGGACGCGGCCT-3'       introduces Phe-105Ala mutation         MUT7       5'-GCTCGGTACCCGGAGATCC-3'       eliminates <i>Bam</i> HI site of pBG15         M4       5'-GAGGAAACAGCTATGAC-3'       Y         RV       5'-CAGGAAACAGCTATGGACGAGACCTATGAC-3'       Y         N0A       5'-GGAGGAAGACATATGAGAGGCCTTATGCTCTAACCT-3'       introduces <i>Ndel</i> site         C0A       5'-GAGATTATGCGAATAATGACGAAGAAATTAAAGTTTGTGT-3'       ATAAGCTCAAGCTTAAGAAGCCTTATGCCTCAACCT-3'         ABRBTOP       5'-GAGATTATGACGAAGAAATGACGAAGAAAT-3'       ABRBBOT         ABRBBOT       5'-ATATATTCCCTATATTGCACAAAATCC-3'       ATNESCC         ATNESGG       5'-ATATATAAGGAATATTAA-3' </td <td></td> <td>Km(1ac), <math>T/promoter = concentration of the first second secon</math></td> <td>This work</td>		Km(1ac), $T/promoter = concentration of the first second secon$	This work
pE10AF     Km, lacl, 1 / promoter, sp00AF105A     This work       pET0ASF1     Km, lacl, T 7 promoter, sp00AF105AQ121R     This work       pET0ASF2     Km', lacl, T 7 promoter, sp00AF105AQ90R     This work       pET0ASF3     Km', lacl, T 7 promoter, sp00AF105AQ90R     This work       pET0ASF4     Km', lacl, T 7 promoter, sp00AF105AQ90R     This work       PET0ASF4     Km', lacl, T 7 promoter, sp00AF105AU162R     This work       0ligonucleotides     This work     This work       R1     S'-TGAGAATAAAGGCGGAGCGCGCCT-3'     Introduces Tyr-104Ala mutation       R2     S'-TGAGAATAGCGTAGGACGCGCCCT-3'     Introduces Tyr-104Ala mutation       MUT7     S'-GCTCGGTACCCGGAGATCC-3'     Introduces Phe-105Ala mutation       MUT7     S'-GGTGCCCGGGAGATCC-3'     Introduces Phe-105Ala mutation       MUT7     S'-GGTTTTCCCAGTCACGAC-3'     Introduces Phe-105Ala mutation       MUT7     S'-GGAGGAACAGCTATGAC-3'     Introduces Ned Site       C0A     S'-GTTTTCCCAGTCACGAC-3'     Introduces Ned Site       C0A     S'-ATAGCTCAAGCTTAAGAAGCCTTATGCTCTAACCT-3'     Introduces HindIII site       ABRBDOT     S'-ATAGCTCCAAGCATATGACGAAGAAAAT-3'     ABRBBOT       S'-ATATATAAGGAATAATGACGAAAAATCC-3'     Introduces HindIII site       ATNESCC     S'-ATATATAAGGAATATTAA-3'	PETUAY	Km, iaci, 17 promoter, spour 104A	
pE10ASF1       Km', <i>lacl</i> ; 17 promoter, <i>sp00AF105AQ121R</i> This work         pET0ASF2       Km', <i>lacl</i> ; T7 promoter, <i>sp00AF105AQ121R</i> This work         pET0ASF3       Km', <i>lacl</i> ; T7 promoter, <i>sp00AF105AQ30R</i> This work         pET0ASF4       Km', <i>lacl</i> ; T7 promoter, <i>sp00AF105AQ30R</i> This work         PET0ASF4       Km', <i>lacl</i> ; T7 promoter, <i>sp00AF105AH162R</i> This work         Oligonucleotides       ************************************	PETUAF	Km', <i>Iaci</i> ; 17 promoter, <i>spouAF105A</i>	This work
pET0ASF2       Km', lac/; 17 promoter, spo0AF105AQ121R       This work         pET0ASF3       Km', lac/; 17 promoter, spo0AF105AQ90R       This work         pET0ASF4       Km', lac/; 17 promoter, spo0AF105AH162R       This work         Oligonucleotides       S'-TGAGAATAAAGGCGGACGCGCCT-3'       introduces Tyr-104Ala mutation         R2       5'-TGAGAATAGCGTAGGACGCGCCT-3'       introduces Tyr-104Ala mutation         MUT7       5'-GCTCGGTACCCGGAGATCC-3'       introduces Phe-105Ala mutation         MUT7       5'-GCTCGGTACCCAGGACGCCCT-3'       introduces Phe-105Ala mutation         MUT7       5'-GCTCGGTACCCAGGAGTCC-3'       introduces Phe-105Ala mutation         MUT7       5'-GCTCGGTACCCAGGACGCCT-3'       introduces Phe-105Ala mutation         MUT7       5'-GCTCGGTACCCAGACACCCGAGAC-3'       Y         RV       5'-GCTGGGAACAGCTTAGAC-3'       Y         N0A       5'-GGAGGAAGACATTGGAGAAAATTAAAGTTTGTGT-3'       introduces Nicel site         C0A       5'-ATAAGCTCAAGCTTAAGAAGCCTTATGCTCTAACCT-3'       introduces HindIII site         ABRBTOP       5'-GGATTTTGCTGATATATGACGAAGAAAAT-3'       ABRBBOT       5'-ATTATAAGGAAATTGCCTTATATCGACAAAATCC-3'         ATNESGG       5'-ATATATAAGGAATTATAA-3'       J       J	pETUASF1	Km', <i>Iaci</i> ; 17 promoter, <i>spouAF105A194M</i>	This work
pETOASF3       Km', laci; T7 promoter, spo0AF105AQ90R       This work         pETOASF4       Km', laci; T7 promoter, spo0AF105AH162R       This work         Oligonucleotides       This work       This work         R1       5'-TGAGAATAAAGGCGGACGCGCCT-3' introduces Tyr-104Ala mutation       F         R2       5'-TGAGAATAGCGTAGGACGCGCGCCT-3' introduces Phe-105Ala mutation       F         MUT7       5'-GCTCGGTACCCCGGAGATCC-3' eliminates BamHI site of pBG15       F         M4       5'-GTTTTCCCAGTCACGAC-3'       F         N0A       5'-GGAGGAAGCATATGGAGAGACATATGAGAGACTTATGAGT-3' introduces Ndel site       F         C0A       5'-ATAAGCTCAAGCTTAGACCTATGCTCTAACCT-3' introduces HindIII site       F         ABRBTOP       5'-GGATTTTGTCGAATAATGACGAAGAAAATTGACGAAGAAAAT-3' ATNESCC       5'-ATTATATCCTTATATAT-3' ATNESGG       S'-ATATATAGGAATATTAA-3'	pET0ASF2	Km <sup>r</sup> , <i>lacl</i> ; T7 promoter, <i>spo0AF105AQ121R</i>	This work
pET0ASF4     Km', lacl; T7 promoter, sp00AF105AH162R     This work       Oligonucleotides     5'-TGAGAATAAAGGCGGACGCGGCCT-3'     Introduces Tyr-104Ala mutation       R2     5'-TGAGAATAGCGTAGGACGCGGCCT-3'     Introduces Tyr-104Ala mutation       MUT7     5'-GCTCGGTACCCGGAGATCC-3'     Introduces Phe-105Ala mutation       MUT7     5'-GCTCGGTACCCGGAGACAC3'     Introduces Phe-105Ala mutation       MUT7     5'-GCTCGGTACCCGGAGACAC3'     Introduces Phe-105Ala mutation       M4     5'-GTTTCCCAGTCACGACC3'     Introduces Phe-105ACCCA3'       N0A     5'-GGAGGACACATATGACGAGAGACACTTAGCTCTAACCT-3'     Introduces Ndel site       C0A     5'-GAGTTTGTCGAATAATGACGAAGACAAATGACGAAAAAT-3'     ABRBBOT       ABRBBOT     5'-GGATTTGTCGAATAATGACGAAAAAT-3'     ABRBBOT       ATNESCC     5'-TTAATATAAGGAATATTAA-3'     Introduces S'-TTAATATAAGGAATATTAA-3'	pET0ASF3	Km <sup>r</sup> , <i>lacl</i> ; T <i>7</i> promoter, <i>spo0AF105AQ90R</i>	This work
Oligonucleotides         R1       5'-TGAGAATAAAGGCGGACGCGCCT-3' introduces Tyr-104Ala mutation         R2       5'-TGAGAATAGCGTAGGACGCGCCCT-3' introduces Phe-105Ala mutation         MUT7       5'-GCTCGGTACCCGGAGATCC-3' eliminates BamHI site of pBG15         M4       5'-GTTTTCCCAGTCACGAC-3'         RV       5'-GGAGGAAGACAGCTATGAC-3'         N0A       5'-GGAGGAAGACATATGGAGAACAGTTATGCTCTAACGT-3' introduces Ndel site         C0A       5'-ATAAGCTCAAGCTAAGAAGCCTTATGCTCTAACCT-3' introduces HindIII site         ABRBTOP       5'-GGATTTTGCCAATAATGACGAAGAAAAT-3' ABRBBOT         S'-TTAATATTCCTTATATAT-3' ATNESCG       5'-ATAAGGAAATATTAA-3'	pET0ASF4	Km <sup>r</sup> , <i>lacl</i> ; T7 promoter, <i>spo0AF105AH162R</i>	This work
R15'-TGAGAATAAAGGCGGACGCGCCT-3' introduces Tyr-104Ala mutationR25'-TGAGAATAGCGTAGGACGCGCCT-3' introduces Phe-105Ala mutationMUT75'-GCTCGGTACCCGGAGATCC-3' eliminates BamHI site of pBG15M45'-GTTTTCCCAGTCACGAC-3'RV5'-CAGGAAACAGCTATGAC-3'N0A5'-GGAGGAAGACATATGGAGAAAATTAAAGTTTGTGT-3' introduces Ndel siteC0A5'-ATAAGCTCAAGCTTAAGAAGCCTTATGCTCTAACCT-3' introduces HindIII siteABRBTOP5'-GGATTTTGCCAATAATGACGAAGAAAAT-3'ABRBBOT5'-TTAATATTCCTTATATAT-3' S'-TTAATATTCCTTATATA-3'	Oligonucleotides		
R2introduces Tyr-104Ala mutationR25'-TGAGAATAGCGTAGGACGCGCCT-3' introduces Phe-105Ala mutationMUT75'-GCTCGGTACCCGGAGATCC-3' eliminates BamHI site of pBG15M45'-GTTTTCCCAGTCACGAC-3'RV5'-CAGGAAACAGCTATGAC-3'N0A5'-GGAGGAAGACATATGGAGAAAATTAAAGTTTGTGT-3' introduces Ndel siteC0A5'-ATAAGCTCAAGACTTAAGAAGCCTTATGCTCTAACCT-3' introduces HindIII siteABRBTOP5'-GGATTTTGTCGAATAATGACGAAGAAAAT-3'ABRBBOT5'-ATAAGCTCAATATGACGAAGAAAAT-3' ATTTSCCAATATTCCTATATTCGACAAAATCC-3' 5'-TTAATATTCCTTATATAT-3'ATNESCG5'-ATAAGGAATATTAA-3'	R1	5'-TGAGAATAAAGGCGGACGCGCCT-3'	
R2       5'-TGAGAATAGCGTAGGACGCGCCT-3' introduces Phe-105Ala mutation         MUT7       5'-GCTCGGTACCCGGAGATCC-3' eliminates BamHI site of pBG15         M4       5'-GTTTTCCCAGTCACGAC-3'         RV       5'-CAGGAACAGCTATGAC-3'         N0A       5'-GGAGGAAGACATATGGAGAAAATTAAAGTTTGTGT-3' introduces Ndel site         C0A       5'-ATAAGCTCAAGCTTAAGAAGCCTTATGCTCTAACCT-3' introduces HindIIII site         ABRBTOP       5'-GGATTTTGTCGAATAATGACGAAGAAAAT-3'         ABRBBOT       5'-ATTATTCCTATTCTCGTCATATTCGACAAAATCC-3' ATNESCC         ATNESGG       5'-ATATAAGGAATATTAA-3'		introduces Tyr-104Ala mutation	
MUT7introduces Phe-105Ala mutationMUT75'-GCTCGGTACCCGGAGATCC-3' eliminates BamHI site of pBG15M45'-GTTTTCCCAGTCACGAC-3'RV5'-CAGGAAACAGCTATGAC-3'N0A5'-GGAGGAAGACATATGGAGAAAATTAAAGTTTGTGT-3' introduces Ndel siteC0A5'-ATAAGCTCAAGCTTAAGAAGCCTTATGCTCTAACCT-3' introduces HindIII siteABRBTOP5'-GGATTTTGTCGAATAATGACGAAGAAAAT-3'ABRBBOT5'-ATTATTCTTCGTCATTATTCGACAAAATCC-3' ATNESCCATNESGG5'-ATAAGGAAGAATATTAA-3'	R2	5'-TGAGAATAGCGTAGGACGCGCCT-3'	
MUT75'-GCTCGGTACCCGGAGATCC-3' eliminates BamHI site of pBG15M45'-GTTTTCCCAGTCACGAC-3'RV5'-CAGGAAACAGCTATGAC-3'N0A5'-GGAGGAGACATATGGAGAAAATTAAAGTTTGTGT-3' introduces Ndel siteC0A5'-ATAAGCTCAAGCTTAAGAAGCCTTATGCTCTAACCT-3' introduces HindIII siteABRBTOP5'-GGATTTTGTCGAATAATGACGAAGAAAAT-3'ABRBBOT5'-ATTATTCCTCATCTTATTCGACAAAAT-3'ATNESCC5'-TTAATATTCCTTATATA-3'		introduces Phe-105Ala mutation	
aliminates BamHI site of pBG15         M4       5'-GTTTTCCCAGTCACGAC-3'         RV       5'-CAGGAAACAGCTATGAC-3'         N0A       5'-GGAGGAAGACATATGGAGAAAATTAAAGTTTGTGT-3'         introduces Ndel site         C0A       5'-ATAAGCTCAAGCTTAGGAGAAGCCTTATGCTCTAACCT-3'         introduces HindIII site         ABRBTOP       5'-GGATTTTGTCGAATAATGACGAAGAAAAT-3'         ABRBBOT       5'-ATTATTCTTCGTCATTATTCGACAAAAT-3'         ATNESCC       5'-TTAATATTCCTTATATA-3'	MUT7	5'-GCTCGGTACCCGGAGATCC-3'	
M4       5'-GTTTTCCCAGTCACGAC-3'         RV       5'-CAGGAAACAGCTATGAC-3'         N0A       5'-GGAGGAAGACATATGGAGAAAATTAAAGTTTGTGT-3'         introduces       Ndel site         C0A       5'-ATAAGCTCAAGCTTAAGAAGCCTTATGCTCTAACCT-3'         introduces       HindIII site         ABRBTOP       5'-GGATTTTGTCGAATAATGACGAAGAAAAT-3'         ABRBBOT       5'-ATTATTCTCGTCATTATTCGACAAAAT-3'         ATNESCC       5'-TTAATATTCCTTATATA-3'		eliminates <i>Bam</i> HI site of pBG15	
NM*       5'-CAGGAAACAGCTATGAC-3'         RV       5'-CAGGAAGACATATGGAGAAAATTAAAGTTTGTGT-3'         N0A       5'-GGAGGAAGACATATGGAGAGAAAATTAAAGTTTGTGT-3'         introduces       Ndel site         C0A       5'-ATAAGCTCAAGCTTAAGAAGCCTTATGCTCTAACCT-3'         introduces       HindIIII site         ABRBTOP       5'-GGATTTGTCGAATAATGACGAAGAAAAT-3'         ABRBBOT       5'-ATTATTCTCGTCATTATTCGACAAAATCC-3'         ATNESCC       5'-TTAATATTCCTTATATAT-3'         ATNESGG       5'-ATTATAAGGAATATTAA-3'	Ma	5'-GTTTTCCCAGTCACGAC-3'	
NOA       5'-GGAGGAAGACATATGAGAGAAAATTAAAGTTTGTGT-3' introduces Ndel site         COA       5'-ATAAGCTCAAGCTTAAGAAGCCTTATGCTCTAACCT-3' introduces HindIII site         ABRBTOP       5'-GGATTTTGTCGAATAATGACGAAGAAAAT-3' ABRBBOT         5'-ATTATTCCTCGTCATTATTCGACAAAAT-3' ATNESCC       5'-TTAATATTCCTTATATA-3' 5'-ATTATAAGGAATAATTAA-3'	BV	5'-CAGGAAACAGCTATGAC-3'	
NDA       5'-GGAGGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGA	NOA		
C0A       5'-ATAAGCTCAAGCTTAAGAAGCCTTATGCTCTAACCT-3'         introduces Hindll site         ABRBTOP       5'-GGATTTTGTCGAATAATGACGAAGAAAAAT-3'         ABRBBOT       5'-ATTTTCTTCGTCATTATTCGACAAAAATCC-3'         ATNESCC       5'-TTAATATTCCTTATATA-3'         ATNESGG       5'-ATATATAAGGAATATTAA-3'	NUA	5-GGAGGAAGACATATGGAGAAAATTAAAGTTTGTGT-5	
ABRBTOP 5'-ATATATCCTTATATCGAAGCCTTATCGAAGCCTTATCGCTCTAACCT-S ABRBBOT 5'-ATTTTTCTTCGTCAATAATGACGAAGAAAAT-3' ATNESCC 5'-TTAATATTCCTTATATAT-3' ATNESGG 5'-ATATATAAGGAATATTAA-3'	C04		
ABRBTOP 5'-GGATTTTGTCGACAAAAATGACGAAGAAAAAT-3' ABRBBOT 5'-ATTTTCTTCGTCATTATTCGACAAAATCC-3' ATNESCC 5'-TTAATATTCCTTATATAT-3' ATNESGG 5'-ATATATAAGGAATATTAA-3'	CUA		
ABHBTOP       5'-GGATTTTGTCGAAIAATGACGAAGAAAAAT-3'         ABRBBOT       5'-ATTTTTCTTCGTCATTATTCGACAAAAATCC-3'         ATNESCC       5'-TTAATATTCCTTATATAT-3'         ATNESGG       5'-ATATATAAGGAATATTAA-3'			
ABHBBOI       5'-ATTTTCTTCGTCATTATTCGACAAAATCC-3'         ATNESCC       5'-TTAATATTCCTTATATAT-3'         ATNESGG       5'-ATATATAAGGAATATTAA-3'	ABREIOP		
ATNESCC 5'-TTAATATTCCTTATATAT-3' ATNESGG 5'-ATATATAAGGAATATTAA-3'	ABRBBOT	5'-ALLEL FOTTCGTCATTATTCGACAAAATCC-3'	
ATNESGG 5'-ATATATAAGGAATATTAA-3'	ATNESCC	5'-TTAATATTCCTTATATAT-3'	
	ATNESGG	5′-ATATATAAGGAATATTAA-3′	

acrylamide gels, and the two forms are not resolved. We therefore treated the samples with limiting concentrations of trypsin, which cleaves Spo0A in the linker region that separates the N- and C-terminal domains (Grimsley *et al.*,

1994; Muchová *et al.*, 1999). The isolated effector domain fragment has a very low mobility in these native gels; moreover, the phosphorylated and unphosphorylated forms of the receiver domain can be clearly resolved. As

Table 2.	Sporulation	efficiency o	f strains wit	th mutations	in Spo0A	compared with	wild-type B. subtilis.
----------	-------------	--------------	---------------	--------------	----------	---------------	------------------------

Strain	Mutation in Spo0A	Other name	Location	Sporulation efficiency (%)
PY 79	Wild type	_		100
IB658	Y104A	_	β5	0.01
IB659	F105A	_	β5	0.002
IB220	spo0A::kan	_		0.0004
IB685 (sfa-1)	F105A, T94M	_	β5, α4	56
IB686 (sfa-2)	F105A, Q121R	<i>sof</i> -108	β5, α5	62
IB687 (sfa-4)	F105A, H162R	suv-4	β5, αΑ	17
IB690 (sfa-3)	F105A, Q90R	<i>coi-</i> 15	β5, β4–α4 loop	18

© 2004 Blackwell Publishing Ltd, Molecular Microbiology, 53, 829-842



**Fig. 1.** Gel filtration chromatograms of Spo0A proteins. Blue, untreated Spo0A proteins; green, Spo0A proteins after incubation for 30 min in the presence of 50 mM phosphoramidate.

A-F. Chromatograms for the following unphosphorylated and phosphorylated Spo0A proteins: (A) wt Spo0A; (B) Spo0A(Y104A); (C) Spo0A(F105A); (D) Sfa-1; (E) Sfa-3; and (F) Sfa-4. The column was run in 20 mM Tris-HCl buffer (pH 7.5), 10 mM MgCl<sub>2</sub> and 250 mM NaCl. The absorbance at 280 nm was recorded in a flow cell with a path length of 2 mm. The solid red trace in (D) corresponds to phosphorylated Sfa-1 protein after treatment with the phosphatase Spo0E. Sfa-2 behaved in the same way as Sfa-3 (E, data not shown). The dotted red lines are the chromatograms for a mixture of molecular weight standards, these being, from left to right, bovine serum albumin (67 000 Da), ovalbumin (43 000 Da) and chymotrypsinogen (25 000 Da). Blue dextran (~ 2000 kDa) was used in order to determine the void volume of the column.

may be seen in Fig. 2 (lanes 1 and 2), treatment of wildtype Spo0A with phosphoramidate causes the mobility of the receiver domain fragment to be noticeably lowered, its  $R_f$  value (relative to bromophenol blue) changing from 0.56 to 0.48. Treatment of the Spo0A(F105A) (Fig. 2, lanes 4 and 5) and Spo0A(Y104A) (Fig. 2, lanes 7 and 8) mutant proteins with phosphoramidate also changed the mobility of the receiver domain fragments generated by proteolysis. In these cases, the change is more modest from  $R_f = 0.56$  for the unphosphorylated species to  $R_f = 0.52$  for the phosphorylated forms.

The lowering of the gel mobility caused by phosphoramidate is more striking for wild-type Spo0A, consistent with the observation that it forms a dimer upon phosphorylation whereas the two mutant proteins do not. It has been shown that dimer formation is mediated by the

Table 3. Molecular	weights of	Spo0A proteins	obtained by gel	filtration and AUC
--------------------	------------	----------------	-----------------	--------------------

Spo0A protein	Unphos	phorylated	Phosphorylated		
	GF retention volume (ml)	AUC molecular weight (kDa)	GF retention volume (ml)	AUC molecular weight (Da)	
Wild type	10.7	27.2	9.3	25.3, 48.4	
Y104A	10.7	26.7	10.5	28.4	
F105A	10.7	25.3	10.1	27.3	
F105A, Q90R (Sfa-3)	10.7	27.3, 25.2ª	9.8	25.2, 48.2	
F105A, T94M (Sfa-1)	10.7	27.2	9.5	45.6	
F105A, Q121R (Sfa-2)	10.7	28.0	9.4	32.1, 57.6	
F105A, H162R (Sfa-4)	10.7	24.8	10.3	29.0, 48.0	

a. Treated with phosphoramidate and then Spo0E94.

© 2004 Blackwell Publishing Ltd, Molecular Microbiology, 53, 829-842



**Fig. 2.** Phosphorylation of wt Spo0A and mutant proteins. Non-denaturing 12.5% PAGE of the Spo0A fragments resulting from digest reactions with trypsin in a ratio of 2500:1. Lanes 1, 4, 7, 10, 13, 16 and 19 represent non-phosphorylated N-Spo0A protein domains. Lanes 2, 5, 8, 11, 14, 17 and 20 are phosphorylated N-Spo0A protein domains after treatment with phosphoramidate. Lanes 3, 6, 9, 12, 15, 18 and 21 are N-Spo0A protein domains after treatment with phosphorylated N-Spo0A. The positions of different forms of N-Spo0A are marked at the left-hand side (A, dimer form of phosphorylated N-Spo0A; B, monomer form of phosphorylated N-Spo0A. The presence of 50 mM phosphoramidate (PA) and/or 5 μM Spo0E94 is indicated + and -, respectively, at the bottom of the figure. Each lane contains 4 μg of protein.

receiver domain (Lewis *et al.*, 2002). The decrease in the gel mobility of the receiver domains of the Spo0A mutants upon phosphorylation results from an increase (+1) in the net charge of the migrating species; the additional negative charge arising from phosphorylation of the carboxylate is offset by the +2 charge of a tightly bound magnesium ion. A decrease in gel mobility was also observed upon phosphorylation of Spo0F (Zapf *et al.*, 1996), which has a very similar tertiary structure to N-Spo0A (Madhusudan *et al.*, 1997), even though Spo0F is a monomer in both unphosphorylated and phosphorylated forms. Thus, the native gel electrophoresis method allows us to distinguish three different forms of N-Spo0A: phosphorylated monomers (Fig. 3, arrows A–C).

To prove that the diminished gel mobilities result from phosphorylation of the active site aspartates, the phosphoramidate-treated protein samples were incubated with Spo0E as described in *Experimental procedures*. It can be seen in Fig. 2 (lanes 3, 6 and 9) that the gel mobilities of the tryptic fragments of all three proteins are restored to those of the unphosphorylated receiver domain fragments. We conclude that each of the three proteins is phosphorylated by phosphoramidate and that the phosphorylated forms are substrates for Spo0E regardless of whether or not they form dimers.

# Spo0A(Y104A) and Spo0A(F105A) do not bind to the abrB promoter

To examine whether the mutant proteins can bind to DNA, we constructed a 30 bp duplex DNA fragment derived from the *abrB* promoter and containing a 0A box sequence (5'-TGACGAA-3') using the synthetic oligonucleotides ABRBTOP and ABRBBOT (Table 1). This DNA fragment was used in gel mobility shift assays. Expression of *abrB* is repressed by Spo0A-P early in sporulation, and the interactions of Spo0A-P with 0A boxes at this promoter have been studied in detail (Strauch *et al.*,

1990). As shown in Fig. 3A (lane 3), the abrB promoter DNA fragment is shifted efficiently by 2.5 ng  $\mu$ l<sup>-1</sup> wild-type Spo0A~P. The same concentrations of Spo0A(Y104A)~P and Spo0A(F105A)~P fail to bring about a gel mobility shift. Weak binding of the mutant proteins is observed only at 10-fold higher concentrations (Fig. 3B and C). No binding to DNA was detected upon incubation with unphosphorylated wild-type Spo0A even at elevated protein concentrations (data not shown). The specificity of the interaction between Spo0A~P and the *abrB* promoter was demonstrated in competition assays in which unlabelled specific and non-specific DNAs were included in the incubation mixes. The non-specific competitor DNA, formed from oligonucleotides ATNESCC and ATNESGG (Table 1), was not able to compete with <sup>32</sup>P-labelled abrB DNA (0.19 pmol) in DNA-Spo0A~P complex formation even when present in 100-fold molar excess (19 pmol) (Fig. 3D). The presence of Spo0A~P in the retarded <sup>32</sup>Plabelled abrB DNA band was confirmed by Western blotting, probing with a polyclonal anti-Spo0A antibody (data not shown).

#### The search for suppressor mutations

If the sporulation defect resulting from the *spo0A*(*F105A*) and *spo0A*(*Y104A*) mutations is caused by the inability of the encoded proteins to dimerize upon phosphorylation, second-site mutations in the dimer-forming surface might be able to compensate for the F105A and Y104A substitutions and restore sporulation. We therefore performed an *in vivo* search for suppressor mutations as described in *Experimental procedures*. In our search for suppressors of *spo0A*(*F105A*), six well-growing colonies were isolated that exhibited a clear Spo<sup>+</sup> phenotype. Back-transformation experiments showed that the sites of all six compensatory suppressor mutations were linked to *spo0A*. Amplification of the *spo0A* region of each of these Spo<sup>+</sup> colonies by polymerase chain reaction (PCR)



#### Fig. 3. Gel mobility shift assay experiments.

A, B, C and E. Binding of phosphorylated Spo0A, Spo0AF105A, Spo0AY104A and suppressor proteins to the *abrB* promoter ( $P_{abrB}$ ). D. The specificity of Spo0A binding to  $P_{abrB}$ . Phosphorylated Spo0A proteins were incubated with 0.19 pmol of <sup>32</sup>P-labelled  $P_{abrB}$  DNA as described in *Experimental procedures*. Reaction mixtures were separated on a native 8% polyacrylamide gel and then analysed by autoradiography. The positions of  $P_{abrB}$  DNA, Spo0A- $P_{abrB}$  complex as well as the origins of the gel lanes are indicated on the right. The direction of migration was towards the anode as indicated on the left. The presence of 19 pmol of specific inhibitor (non-labelled  $P_{abrB}$ ) or 19 pmol of non-specific inhibitor is indicated + and –, respectively, at the bottom of the autoradiogram. The amount of protein used for the experiments in (D) was 50 ng in lanes 1–3. Increasing amounts of protein was used for (A), (B), (C) and (E) as follows: lanes 1 and 2, 20 ng; lanes 3 and 4, 50 ng; lanes 5 and 6, 200 ng; and lanes 7 and 8, 500 ng.

and subsequent DNA sequencing of the entire coding regions revealed that the suppressor mutations were at four different sites (Table 2). Three of the six isolates shared a mutation at codon 94: an ACG transitional mutation to ATG, corresponding to a threonine to methionine substitution. We have named this mutation sfa-1 (suppressor of E105A mutation). Two other suppressor mutations, Gln-121Arg (*sfa-2*) and Gln-90Arg (*sfa-3*), mapped to the N-terminal domain of Spo0A. The fourth suppressor mutation, His-162Arg (*sfa-4*), mapped to the C-terminal domain. The characteristics of the suppressor mutants are

listed in Table 2, and the location of the second-site mutations in the structure of Spo0A is indicated in Fig. 4. These suppressor mutations restore the sporulation efficiency of spo0A(F105A) to between 17% and 62% of that of wildtype spo0A strains (Table 2).

Despite multiple efforts, we were not able to isolate any suppressor mutations of *spo0A(Y104A)*, arguing that it is impossible to compensate for the substitution of this tyrosine by alanine, at least by the subset of amino acid codons accessible by a single base change within the spectrum of the mutagenesis protocol.





B. Close-up views of the proposed dimer interface of Spo0A. The panel on the left is in the same orientation as Fig. 4A, and the panel on the right is orthogonal to this, looking down from above (compare this panel with fig. 2 of Birck *et al.*, 1999). Ball and stick models indicate the positions of Y104 and F105 (dark blue) and the three Sfa suppressors (green) in the receiver domain and the proximity of Sfa-1 (T94M) and Sfa-3 (Q90R) to the dimer interface.

## Characterization of the suppressor mutant proteins

To elucidate how the suppressor mutations restore sporulation, we overexpressed and purified Sfa-1, Sfa-2, Sfa-3 and Sfa-4 proteins and characterized them in vitro as described above for the single mutants. Gel filtration experiments showed that all four of the purified suppressor mutant proteins have retention volumes similar to those of wild-type Spo0A and Spo0A(F105A), suggesting that these proteins are monomers. After treatment with phosphoramidate, the retention volumes of Sfa-1(F105A, T94M), Sfa-2(F105A, Q121R) and Sfa-3(F105A, Q90R) were markedly lowered indicating a preponderance of dimers. Their retention volumes of 9.5, 9.4 and 9.8 ml, respectively, are lower than that of Spo0A(F105A)~P (10.1 ml) and closer to that of wild-type Spo0A~P (9.3 ml; Fig. 1, Table 3). In contrast, the retention volume for Sfa-4(F105A, H162R) is higher at 10.3 ml (Fig. 1, Table 3).

Sedimentation velocity AUC experiments with all four suppressor mutant proteins confirmed that they are monomers in the unphosphorylated form (Table 3). The phosphorylated forms of Sfa-1(F105A, T94M), Sfa-2(F105A, Q121R) and Sfa-3(F105A, Q90R) have higher molecular masses, 45–57 kDa, similar to the wild-type Spo0A dimer (Table 3). The smallest change in molecular mass after phosphorylation was observed in the case of Sfa-4(F015A, H162R), which stays predominantly in the form of a monomer upon phosphorylation (Table 3). All these results are consistent with those observed by gel filtration (Fig. 1).

Non-denaturing PAGE of the trypsin-generated receiver domains also indicated that dimer formation is restored in Sfa-1(F105A, T94M), Sfa-2(F105A, Q121R) and Sfa-3(F105A, Q90R) after phosphorylation by phosphoramidate (Fig. 2, lanes 20, 17 and 14 respectively). The phosphoramidate-treated proteins are substrates for Spo0E, which stimulated the dissociation of the dimer forms of the N-Spo0A mutants to monomers, as observed with wildtype N-Spo0A (Fig. 2, lanes 3, 15, 18 and 21). In contrast, the mobility of Sfa-4(F105A, H162R) in these gels is indistinguishable from that of Spo0A(F105A), suggesting that the receiver domain of this protein is impaired in dimer formation after phosphorylation (Fig. 2, lane 11).

To test the DNA-binding characteristics of the phosphorylated suppressor proteins, we have performed gel mobility shift assays using an *abrB* promoter DNA. The experiments clearly show that all four phosphorylated suppressor proteins bind the *abrB* promoter fragment, albeit less efficiently than the wild-type protein (Fig. 3A and E). The band associated with the complex after incubation with 50 ng of protein is noticeably fainter for the mutants than it is for wild-type Spo0A (Fig. 3A and E). Phosphorylated Sfa-3(F105A, Q90R) and Sfa-4(F105A, H162R) bind the DNA fragment less tightly than Sfa-1(F105A, T94M) and Sfa-2(F105A, Q121R), and higher protein concentrations are required to shift the same fraction of the DNA.

#### Discussion

# Defects in dimerization impair interdomain signal transduction

In this study, we have investigated the contributions of Tyr-104 and Phe-105 to Spo0A function. These residues are found on strand  $\beta 5$  at the heart of the  $\alpha_4\beta_5\alpha_5$  surface (the '455' face) of the protein. Across the response regulator family, there is abundant evidence suggesting that this surface is important in the molecular events that follow phosphorylation (Zapf et al., 2000; Park et al., 2002; Gardino et al., 2003; Hastings et al., 2003). Residues from α4 and B5 of CheY interact with the P2 domain of CheA (McEvoy et al., 1998), and a similar set of residues found in helix  $\alpha$ 4 and strand  $\beta$ 5 of beryllofluoride-activated CheY mediates binding of the flagellar motor protein, FliM (Lee et al., 2001). In the chemotaxis response regulator, CheB, helix  $\alpha 4$  and strand  $\beta 5$  form part of the surface of the receiver domain that inhibits its methylesterase effector domain (Djordjevic et al., 1998). The dimerization of FixJ is mediated by residues situated on helix  $\alpha 4$  and strand β5 of the receiver domain (Birck et al., 1999; Da Re et al., 1999). A key residue in the FixJ dimer interface is Asp-100, which corresponds to Tyr-104 of Spo0A (Birck et al., 1999). Finally, in Spo0A itself, phosphorylation of the receiver domain leads to marked structural changes in the vicinity of Phe-105.

Cells harbouring the spo0A(F105A) and spo0A(Y104A) alleles are severely impaired in sporulation (Table 2). The similarity in the behaviour of Spo0A(F105A) and Spo0A(Y104A) to wild-type Spo0A in the course of purification and their capacity to participate in phosphotransfer reactions suggest that loss of biological function in the mutant proteins is not caused by folding defects. Gel filtration, AUC and electrophoresis experiments reveal that these mutant proteins are impaired in phosphorylationmediated dimer formation relative to the wild-type Spo0A (Table 3; Figs 1 and 2). This may account for their failure to bind to the abrB promoter in gel mobility shift experiments (Fig. 3). Our results clearly show that cells with Spo0A~P monomers are deficient in sporulation and cells with Spo0A~P dimers sporulate. These observations indicate that dimerization is a key link between phosphorylation, sequence-specific DNA binding and transcription regulation by Spo0A.

# Suppressors of spo0A(F105A) reveal important residues for interdomain signalling

Our results suggest that both Spo0A(Y104A) and Spo0A(F105A) are defective in intramolecular domain-

domain signalling; phosphorylation in the receiver domain does not lead to DNA binding by the effector domain. To explore this further, we searched for suppressor mutations that restore the function of the mutant Spo0A proteins *in vivo*. Surprisingly, we isolated *spo*<sup>+</sup> colonies only for strain IB659, which carries the *spo0A*(*F105A*) allele. We found four different intragenic suppressor mutations, with the second-site mutation in three of them (*sfa-1*, *sfa-2* and *sfa-3*) mapping to the receiver domain and that in the fourth (*sfa-4*) mapping to the effector domain of Spo0A (Table 2).

What is the mechanism of suppression? If the effect of the Phe-105Ala mutation is simply to destabilize the dimer form of Spo0A~P, we would expect that mutations elsewhere on the dimer interface might restore function by providing compensating intermolecular contacts that restore dimer stability. Equally, if the effect of the Phe-105Ala mutation is to strengthen intramolecular domain– domain interactions in Spo0A that sequester the effector domain in an inactive state, mutations elsewhere on this surface that weaken domain–domain interactions would help to restore function. As it is possible that the '455' surface, on to which our mutations map, is used in both intra- and intermolecular contacts, distinguishing between these possibilities is not easy.

The locations of the mutations in the crystal structure are indicated in Fig. 4, which shows a model for the Spo0A dimer built with reference to the crystal structures of (i) N-FixJ~P in which the 455 face of the molecule mediates contacts between a pair of receiver domains related by a dyad axis of symmetry (Birck et al., 1999); and (ii) C-Spo0A bound to DNA in which a pair of effector domains sits side-by-side on the DNA (Zhao et al., 2002). An interesting feature of the model is the contrasting head-to-head organization of the receiver domains and the head-to-tail organization of the effector domains (Lewis et al., 2001). This is expected to be facilitated by the extended linker connecting the two domains that confers conformational independence in the phosphorylated form. The variability in the length and sequence of the linker (Brown et al., 1994) is consistent with the absence of defined structure in the interdomain peptide. The data presented here are interpreted in terms of the model presented in Fig. 4 and structural knowledge of how phosphorylation of the active site aspartic acid residue influences the 455 interface in Spo0A.

A comparison of the crystal structures of phosphorylated and unphosphorylated N-Spo0A reveals that the outward to inward movement of the side-chain of Phe-105 (marked 'F' in Fig. 4) upon phosphorylation can be accommodated only if helix  $\alpha$ 4 moves away from the protein core. There would otherwise be severe steric hindrance to the inward movement of Phe-105 by Thr-94, which lies on the inside face of helix  $\alpha$ 4. The movement of  $\alpha$ 4 is hinged towards the C-terminus of the helix, with Ala-97 acting as the fulcrum. The aromatic ring of Phe-105 fills the void created by the movement of Thr-84 towards the aspartyl-phosphate, and we can envisage how this could be mimicked in the Ala-105 mutant if Thr-94 is replaced by the bulkier methionine residue in Sfa-1 (marked '1' in Fig. 4).

Sfa-3 also forms dimers upon phosphorylation (Figs 1 and 2, Table 3). Gln-90, which is substituted by Arg in Sfa-3 (marked '3' in Fig. 4) is situated on helix  $\alpha$ 4. As this is part of the proposed dimer interface (Fig. 4), it is conceivable that the mutation strengthens the dimer interface and compensates for the disruption caused by replacement of Phe-105 by Ala. It is interesting to note that the corresponding residue in Spo0F is Glu-86. Alanine substitution of this residue in Spo0F leads to a sporulation-defective phenotype (Tzeng and Hoch, 1997). In the Spo0F-Spo0B complex, Glu-86 of Spo0F is adjacent to the Spo0B binding surface (Zapf et al., 2000). Mutation to alanine may therefore alter the kinetics of phosphotransfer between Spo0F and Spo0B. The Gln-90 to Arg substitution associated with sfa-3 is obviously similar to the GIn-90 to Lys change encoded in the coi-15 allele of spo0A. A characteristic of coi mutants is 'inappropriate sporulation' in which normal nutritional signals are not required (Olmedo et al., 1990). Although the suppressor mutation in Sfa-2 (marked '2' in Fig. 4) also enables Spo0A harbouring Ala-105 to dimerize, Arg-121, which is on helix-5, is not integral to the dimer interface in our model. It may be that this suppressor acts by destabilizing intramolecular domaindomain interactions. Genetic evidence suggests that helix-5 is involved in interdomain interactions in PhoB (Allen et al., 2001), and mutation of a residue (Thr-109) on this same helix increases the affinity of FixJ for DNA (Saito et al., 2003). The GIn-121 to Arg substitution occurs elsewhere as a single substitution mutation in the Spo0A variant, Sof-108. sof108 strains can sporulate even when spo0F has been deleted (sof - suppressor of spo0F deletion; Spiegelman et al., 1990; Cervin and Spiegelman, 1999). It is assumed, but not proved, that the Arg-121 mutation allows Spo0A to receive the phosphoryl group directly from one of the sporulation sensor kinases. Bypass of the phosphorelay may therefore also take place with Sfa-2. The fact that we could not isolate any suppressors of the Tyr-104 to Ala mutation reinforces the notion that this residue is important for Spo0A function. Tyr-104 is invariant among the 23 Spo0A orthologues sequenced to date, although it is not conserved across the response regulator family, implying that this residue has a discrete function in Spo0A. This residue appears to have coevolved with the effector domains in response regulators. In >95% of CheB sequences, the equivalent residue is aspartic acid, as it is in all OmpR, PhoB and FixJ sequences, whereas glycine is found at the equivalent position in the NarL, GacA, UhpA, LuxR and DegU subfamilies. Glycine is also commonly found at this position within the CheY subfamily, allowing the close approach of Leu-15 of the FliM peptide (Lee *et al.*, 2001). Hence, within response regulator subfamilies, this residue is conserved, while variance is permitted across the whole family. This pattern of conservation across families of response regulators argues that the equivalent residue in other response regulators has an important – but not necessarily the same – role.

The most surprising suppressor is sfa-4 in which the suppressing mutation is His-162 (marked '4' in Fig. 4) to Arg. His-162 is located in the C-terminal domain of Spo0A. This same mutation was isolated previously as a suppressor of spo0A9V (Ala-257Val) and Ser-250His (Perego et al., 1991; Schmeisser et al., 2000). This mutation is only the second intragenic spoOA suppressor that lies in the opposing domain to the original mutation. The other, sof114 (Asp-92Tyr), was isolated as a suppressor of spo0A9V (Perego et al., 1991). Asp-92 is also situated on helix  $\alpha 4$ , sandwiched between Gln-90 and Thr-94, which are mutated in sfa-1 and sfa-3 respectively. Although Phe-105 and Asp-92 are situated on the same protein '455' face, His-162 (site of sfa-4) and Ala-257 (site of spo0A9V) are on opposite sides of the effector domain, and it is not possible for both His-162 and Ala-257 simultaneously to contact the '455' signalling surface within a monomer. However, in a Spo0A dimer, intermolecular contacts between residues His-162 and Ala-257 could occur, as revealed by the crystal structure of C-Spo0A in complex with DNA (Zhao et al., 2002). Similar interactions may also explain the suppression by suv-3 and suv-4 of the Ser-250His and spo0A9V mutations (Schmeisser et al., 2000).

# Model of Spo0A activation through phosphorylation and dimerization

We propose the following model of Spo0A action (Fig. 4). Spo0A becomes phosphorylated by the phosphorelay on Asp-56, and the concomitant conformational changes, mediated via Thr-84 and Phe-105 side-chain movements, result in dimerization. Dimerization disrupts transcriptioninhibitory contacts between the receiver and effector domains of Spo0A. The most important dimer-forming contacts involve the N-terminal domains with additional dimer contacts mediated through the C-terminal domains upon binding to DNA (Lewis et al., 2002; Zhao et al., 2002). Dimerization thus activates the DNA-binding and transcription activation/repression functions of the effector domain. According to the structural and mutagenesis studies, helix a4 of N-Spo0A may be involved not only in dimerization, but also in contacts with the effector domain before activation. Such a model is supported by the data on suppressor mutants, such as suv-3, suv-4, sof-114 and sfa-4. In addition to helix  $\alpha$ 4, other regions of the receiver domain, such as the surface encompassing Asp-75, may be involved in interactions with the effector domain (Cervin and Spiegelman, 2000).

The biochemical characterization of a variety of Spo0A variants, in which the genetic lesions are located in the receiver domain (Cervin and Spiegelman, 1999; 2000), together with the structure of N-Spo0A~P (Lewis et al., 1999), reinforces the significance of phosphorylationinduced conformational changes in the receiver domain for the activation of the effector domain. Complex structural changes in Spo0A must occur on phosphorylation, involving changes in intramolecular contacts and dimerization. Helices  $\alpha A$ ,  $\alpha B$  and  $\alpha F$  of the effector domain and  $\alpha 4$  of the receiver domain appear to be important constituents of the signal transduction pathway in Spo0A. The molecular mechanism of transduction of the phosphorylation signal from N-Spo0A to C-Spo0A is the crucial, unanswered question concerning the function of Spo0A.

# **Experimental procedures**

# Bacterial strains, culture media and genetic techniques

All bacterial strains and plasmids used in this study are listed in Table 1. Unless otherwise indicated, *E. coli* and *B. subtilis* cultures were grown in LB medium (Ausubel *et al.*, 1987). Transformation of *B. subtilis* and assays of sporulation efficiency were performed as described previously (Harwood and Cutting, 1990). Sporulation was induced by nutrient exhaustion in Difco sporulation medium (DSM). After 24 h incubation at 37°C, aliquots of the culture were serially diluted and plated on to LB plates before and after a 15 min incubation at 80°C. The sporulation efficiency was defined in terms of colony-forming units (cfu) as follows: (cfu of spores/viable cfu)/(wt viable spores/wt total viable cfu).

# Site-directed mutagenesis and DNA sequencing

Site-directed mutagenesis of spo0A was carried out with the LA PCR in vitro mutagenesis kit (TaKaRa) according to the manufacturer's instructions. The integrative plasmid pBG15, which contains a promoterless spo0A gene on a 1.9 kb BamHI-HindIII fragment, was used as the template for the PCRs. Suitable mutagenic oligonucleotides were designed to introduce alanine substitutions at Tyr-104 and Phe-105, each introducing a double base change, in anticipation of a subsequent search for suppressor mutations. Each of the two PCR products was digested with BamHI and HindIII and recloned into pBG15 digested with the same restriction enzymes, creating plasmids pBG15YA (Tyr-104Ala) and pBG15FA (Phe-105Ala). After exposure of the ligation products to competent E. coli strain MM294, several ampicillinresistant transformants were isolated, analysed and subsequently sequenced by the dideoxy chain termination reaction. The DNA sequences of all the primers used are listed in Table 1. Plasmids pBG15YA and pBG15FA were each used

to transform the wild-type *B. subtilis* strain PY79 to chloramphenicol resistance. Transformants arising from a single cross-over recombination event created the strains IB658 and IB659 respectively. The sporulation efficiency of these strains was analysed as described above.

### Plasmid constructions

The mutated *spo0A* genes were amplified by PCR using the primers N0A and C0A (Table 1) to introduce flanking *Ndel* and *Hin*dIII sites for subsequent insertion between these same sites in pET26b(+) (Novagen). This generated the plasmids pET0AY, pET0AF, pET0ASF1, pET0ASF2, pET0ASF3 and pET0ASF4. Several clones were obtained, analysed and sequenced to verify that no inadvertent, PCR-derived mutations had arisen.

#### Protein isolation and purification

Cultures of E. coli strain BL21 (DE3) harbouring the pETOA derivatives were grown at 37°C in LB media containing  $30 \ \mu g \ ml^{-1}$  kanamycin until an optical density of 0.6 at 600 nm (OD<sub>600</sub>) was reached. Recombinant protein expression was induced by the addition of IPTG to a final concentration of 1 mM. After 4 h of further growth at 30°C, cells were harvested by centrifugation, and the cell pellets were frozen at -70°C until use. Cell pellets were resuspended in 10 ml of buffer A [20 mM Tris-HCl, pH 7.5, 2 mM EDTA, 2 mM dithiothreitol (DTT), 250 mM NaCl, 1 mM AEBSF] before disruption by sonication. The cell lysate was clarified by centrifugation before loading on to a Heparin Sepharose column, preequilibrated in buffer A. Mutant Spo0A proteins were eluted in buffer A with a linear gradient of 250-1000 mM NaCl. Fractions containing Spo0A were pooled and concentrated before further purification using a Superdex S75 16/60 gel filtration column. Purified proteins were stored at -20°C in filtration buffer, supplemented with glycerol (10% v/v).

## Spo0A phosphorylation and dephosphorylation

Spo0A proteins were treated with phosphoramidate, which can serve as a specific phosphoryl group donor for the activesite aspartate residues in a number of response regulators (Buckler and Stock, 2000). Protein samples were concentrated to 1 mg ml<sup>-1</sup> in a buffer of 20 mM Tris-HCl, pH 7.5, 2 mM DTT, 250 mM NaCl, 10 mM MgCl<sub>2</sub>. Phosphorylation was achieved by the addition of phosphoramidate to a final concentration of 50 mM for 30 min at 37°C (Lewis et al., 2002). After removal of phosphoramidate by Sephadex G-25, samples were placed on ice before further immediate analysis by analytical ultracentrifugation, gel filtration experiments, DNA binding or trypsin digestion, followed by electrophoresis. Dephosphorylation of wild-type Spo0A and mutant proteins was performed with a hyperactive form of Spo0E, Spo0E94, as described previously (Lewis et al., 2002). Spo0A (30 µM) samples were dephosphorylated by Spo0E94 at the final concentration of 5 µM for native PAGE experiments, and 550 µM Spo0A samples were dephosphorylated by Spo0E94 at the final concentration of 100 µM for gel filtration experiments.

### Proteolysis of intact Spo0A

Spo0A proteins were incubated with trypsin at a molar ratio of 2500:1 at 16°C (Muchová *et al.*, 1999) in 20 mM Tris-HCl, pH 7.5, 10 mM MgCl<sub>2</sub>, 100 mM NaCl, 1 mM DTT. The digestion products were immediately analysed by non-denaturing, 12.5% PAGE.

#### Analytical ultracentrifugation

Sedimentation velocity experiments were performed in a Beckman XL/I analytical ultracentrifuge. Protein samples were prepared with A<sub>280</sub> readings of 0.2 for Spo0A(Y104A) and Spo0A(F105A), 0.5 for Sfa-2, 0.8 for Sfa-4, 1.0 for Sfa-3 and 1.2 for wild-type Spo0A, corresponding to concentrations of 5, 5, 12.5, 20, 25 and 30 µM. Unphosphorylated Spo0A samples were prepared in 20 mM Tris-HCl, pH 7.5, 250 mM NaCl, 2 mM EDTA, phosphorylated protein in the same buffer with the addition of 25 mM MgCl<sub>2</sub> and 50 mM phosphoramidate, and Spo0E-treated samples as for the phosphorylated protein with the addition of the protein phosphatase. Protein samples ( $\approx 400 \, \mu l$ ) were centrifuged in charcoal-filled Epon double-sector centrepieces with identical buffers as reference, at 40 000 r.p.m. Sedimentation was observed by scanning absorbance at 280 nm until the plateau region was lost. Data were analysed with the program SEDFIT (Schuck, 2000) using a simple c(s) model (distribution of sedimentation coefficients without assumption of size or number of species) then transformed to c(M) (distribution of molecular weight). The calculated molecular weights depend on the partial specific volume, and buffer density and viscosity were calculated using the program SEDNTERP (Laue et al., 1992) using phosphate for phosphoramidate and neglecting the contribution from Spo0E where used.

# In vivo mutagenesis using ethyl methanesulphonate (EMS)

Strains IB658 and IB659 were mutagenized by plating on DSM agar plates containing appropriate antibiotics and incubated at 30°C overnight. A sterile piece of filter paper with a diameter of  $\approx 1$  cm was placed on the surface of the cell lawn. A volume of 20–35 µl of ethyl methanesulphonate (EMS) was dropped onto the filter paper, and the cultures were incubated at 37°C. After incubation for 24 or 36 h, plates were exposed to chloroform vapour for 15 min to kill non-sporulating cells. The plates were incubated further overnight at 37°C to allow outgrowth of possible spores. Single colonies were picked from these DSM plates and streaked out on to LB plates containing the appropriate antibiotics. Chromosomal DNA was prepared from each of the single colonies and used as the template for PCRs to amplify the spo0A gene for DNA sequencing in order to determine the presence and sequence of the intragenic suppressors.

# DNA preparation for the gel mobility shift assays

An aliquot of 100 ng (11 pmol) of ABRBTOP oligonucleotide (Table 1) was heated for 5 min at 95°C, quickly cooled in an ice bath and labelled with 20  $\mu$ Ci (5 pmol) of [ $\gamma$ -<sup>32</sup>P]-ATP (ICN;

## 840 K. Muchová et al.

4000 Ci mmol<sup>-1</sup>) in a total volume of 25 μl (Ausubel *et al.*, 1987). The incorporation of radioactive label to DNA was determined (Kormanec and Farkasovsky, 1993) before mixing the labelled ABRBTOP oligonucleotide with an equimolar amount of ABRBBOT oligonucleotide (Table 1). This mixture was heated for 5 min at 95°C, annealed for 20 min at 65°C and slowly cooled to 20°C. Unincorporated radionucleotides were removed from duplex DNA by desalting using Sephadex G-50 microtip columns. Specific competitor DNA was prepared by the same annealing procedure using unlabelled *abrB*-specific oligonucleotides. Non-specific competitor DNA was prepared by annealing equimolar amounts of the ATNESCC and ATNESGG oligonucleotides (Table 1) at an annealing temperature 35°C.

# Gel mobility shift assays

Gel mobility shift assays were performed essentially as described by Ausubel et al. (1987). Protein samples were incubated with 20 000 c.p.m. (0.19 ng) of <sup>32</sup>P-labelled abrBspecific DNA with or without competitor DNA for 20 min at 30°C in a solution containing 40 mM Tris-acetate, pH 8.0, 40 mM sodium acetate, 10 mM magnesium acetate, 0.1 mM DTT, 10 µg ml<sup>-1</sup> BSA, 1 mM EDTA and 5% (v/v) glycerol in a total volume of 20 µl. Spo0A and the mutant Spo0A proteins were phosphorylated with phosphoramidate before the binding reaction as described above. Samples were loaded on to an 8% polyacrylamide gel in 1× TAE buffer (40 mM Tris, 20 mM acetic acid, 1 mM EDTA, pH 7.9) containing 2% (v/v) glycerol. The gel was electrophoresed at 30°C and 150 V in 1× TAE buffer until the bromophenol blue had migrated to within 2 cm from the bottom of the gel. The gel was then transferred to Whatman paper, dried and analysed by autoradiography.

## Western blot analysis

Gel mobility shift assays were carried out as described above with 50  $\mu$ g of Spo0A per reaction. The part of the gel destined for blotting was cut from the rest of the gel, and the products of the binding reaction were transferred to a PROTRAN BA 85 (NC) membrane by a semi-dry blotting procedure. Immunodetection of Spo0A was carried out with a polyclonal anti-Spo0A antibody (rabbit) diluted 1:500 in blocking buffer followed by anti-rabbit IgG–alkaline phosphatase reaction.

## Gel filtration

Samples of 100  $\mu$ l of each Spo0A protein, at concentrations of 550  $\mu$ M, were applied to a Pharmacia Superdex 75 HR 10/30 gel filtration column, equilibrated in a buffer containing 20 mM Tris-HCI, pH 7.5, 10 mM MgCl<sub>2</sub>, 250 mM NaCl. According to the manufacturer, this column effectively separates globular proteins in the molecular weight range 3000–70 000 Da.

#### Acknowledgements

We thank Marta Perego for supplying us with the clone for Spo0E94 protein expression, and Philip Youngman for Spo0A

antibody. We thank George Spiegelman for helpful advice on gel mobility shift assays. We also thank David Scott and Anna Ferguson for preliminary AUC experiments. This work was supported by grant 2/1004/22 from the Slovak Academy of Sciences and Wellcome Trust Project and Collaborative Research Initiative Grants (056247/Z/98/Z and 066732/Z/01/ Z respectively). R.J.L. is currently a Wellcome Trust Research Career Development Fellow. J.A.B. was funded by the BBSRC York Structural Biology Centre.

#### References

- Allen, M.P., Zumbrennen, K.B., and McCleary, W.R. (2001) Genetic evidence that the  $\alpha$ 5 helix of the receiver domain of PhoB is involved in interdomain interactions. *J Bacteriol* **183:** 2204–2211.
- Asayama, M., Yamamoto, A., and Kobayashi, Y. (1995) Dimer form of phosphorylated Spo0A, a transcriptional regulator, stimulates the *spo0F* transcription at the initiation of sporulation in *Bacillus subtilis*. J Mol Biol **250**: 11–23.
- Ausubel, F.M., Brent, R., Kingston, R.E., Moore, D.O., Seidmann, J.S., Smith, J., and Struhl, K. (1987) *Current Protocols in Molecular Biology*. New York: Wiley.
- Backman, K., Ptashne, M., and Gilbert, A.W. (1976) Construction of plasmids carrying the *cl* gene of bacteriophage lambda. *Proc Natl Acad Sci USA* **73:** 4174–4178.
- Birck, C., Mourey, L., Gouet, P., Fabry, B., Schumacher, J., Rousseau, P., *et al.* (1999) Conformational changes induced by phosphorylation of the FixJ receiver domain. *Structure* 7: 1505–1515.
- Brown, D.P., Ganova-Raeva, L., Green, B.D., Wilkinson, S.R., Young, M., and Youngman, P. (1994) Characterization of Spo0A homologs in diverse *Bacillus and Clostridium* species identifies a probable DNA-binding domain. *Mol Microbiol* **14**: 411–426.
- Buckler, D.R., and Stock, A.M. (2000) Synthesis of [<sup>32</sup>P] phosphoramidate for use as a low molecular weight phosphodonor reagent. *Anal Biochem* **283:** 222–227.
- Cervin, M.A., and Spiegelman, G.B. (1999) The Spo0A *sof* mutations reveal regions of the regulatory domain that interact with a sensor kinase and RNA polymerase. *Mol Microbiol* **31:** 597–607.
- Cervin, M.A., and Spiegelman, G.B. (2000) A role for Asp<sup>75</sup> in domain interaction in the *Bacillus subtilis* response regulator Spo0A. *J Biol Chem* **275**: 22025–22030.
- Cho, H.S., Pelton, J.G., Yan, D., Kustu, S., and Wemmer, D.E. (2001) Phosphoaspartates in bacterial signal transduction. *Curr Opin Struct Biol* **11**: 679–684.
- Chung, J.D., Stephanopoulos, G., Ireton, K., and Grossman, A.D. (1994) Gene expression in single cells of *Bacillus subtilis*: evidence that a threshold mechanism controls the initiation of sporulation. *J Bacteriol* **176:** 1977–1984.
- Da Re, S., Schumacher, J., Rousseau, P., Fourment, J., Ebel, C., and Kahn, D. (1999) Phosphorylation-induced dimerization of the FixJ receiver domain. *Mol Microbiol* 34: 504–511.
- Djordjevic, S., Goudreau, P.N., Xu, Q., Stock, A.M., and West, A.H. (1998) Structural basis for methylesterase CheB regulation by a phosphorylation-activated domain. *Proc Natl Acad Sci USA* **95:** 1381–1386.

- Ellison, D.W., and McCleary, W.R. (2000) The unphosphorylated receiver domain of PhoB silences the activity of its output domain. *J Bacteriol* **182:** 6592–6597.
- Fawcett, P., Eichenberger, P., Losick, R., and Youngman, P. (2000) The transcriptional profile of early to middle sporulation in *Bacillus subtilis. Proc Natl Acad Sci USA* **97**: 8063–8068.
- Florek, P., Muchová, K., and Barák, I. (2002) Truncated Spo0A transcription activities in *Bacillus subtilis. Biologia* (*Bratislava*) **57:** 805–811.
- Gardino, A.K., Volkman, B.F., Cho, H.-S., Lee, S.Y., Wemmer, D.E., and Kern, D. (2003) The NMR solution structure of BeF<sub>3</sub>-activated Spo0F reveals the conformational switch in a phosphorelay system. *J Mol Biol* **331**: 245–254.
- Grimsley, J.K., Tjalkens, R.B., Strauch, M.A., Bird, T.H., Spiegelman, G.B., Hostomsky, Z., *et al.* (1994) Subunit composition and domain structure of the Spo0A sporulation transcription factor of *Bacillus subtilis. J Biol Chem* **269:** 16977–16982.
- Harwood, C.R., and Cutting, S.M. (eds) (1990) *Molecular Biological Methods for Bacillus*. Chichester: John Wiley and Sons.
- Hastings, C.A., Lee, S.Y., Cho, H.S., Yan, D., Kustu, S., and Wemmer, D.E. (2003) High-resolution structure of the beryllofluoride-activated NtrC receiver domain. *Biochemistry* **42**: 9081–9090.
- Ireton, K., Rudner, D.Z., Siranosian, K.J., and Grossman, A.D. (1993) Integration of multiple developmental signals in *Bacillus subtilis* through the Spo0A transcription factor. *Genes Dev* **7:** 283–294.
- Jiang, M., Shao, W., Perego, M., and Hoch, J.A. (2000) Multiple histidine kinases regulate entry into stationary phase and sporulation in *Bacillus subtilis*. *Mol Microbiol* **38**: 535–542.
- Kormanec, J., and Farkasovsky, M. (1993) Simple and reliable determination of radioactive precursor-incorporation into nucleic acids *in vitro*. *Biotechniques* **15**: 400.
- Ladds, J., Muchová, K., Blaskovic, D., Lewis, R.J., Brannigan, J.A., Wilkinson, A.J., and Barák, I. (2003) The response regulator Spo0A from *Bacillus subtilis* is efficiently phosphorylated in *Escherichia coli. FEMS Microbiol Lett* 223: 153–157.
- Laue, T.M., Shah, B.D., Ridgeway, T.M., and Pelletier, S.L. (1992) Computer aided interpretation of analytical sedimentation data for proteins. In *Analytical Ultracentrifugation in Biochemistry and Polymer Science*. Harding, S.E., Rowe, A.J., and Horton, J.C. (eds). Cambridge: Royal Society of Chemistry, pp. 90–125.
- Lee, S.Y., Cho, H.S., Pelton, J.G., Yan, D., Henderson, R.K., King, D.S., *et al.* (2001) Crystal structure of an activated response regulator bound to its target. *Nature Struct Biol* 8: 52–56.
- Lewis, R.J., Brannigan, J.A., Muchová, K., Barák, I., and Wilkinson, A.J. (1999) Phosphorylated aspartate in the structure of a response regulator protein. *J Mol Biol* 294: 9–15.
- Lewis, R.J., Muchová, K., Brannigan, J.A., Barák, I., Leonard, G., and Wilkinson, A.J. (2000a) Domain swapping in the sporulation response regulator, Spo0A. *J Mol Biol* 297: 757–770.
- Lewis, R.J., Krzwyda, S., Brannigan, J.A., Turkenburg, J.P.,
- © 2004 Blackwell Publishing Ltd, Molecular Microbiology, 53, 829-842

Muchová, K., Dodson, E.J., *et al.* (2000b) The *trans*activation domain of the sporulation response regulator Spo0A, revealed by X-ray crystallography. *Mol Microbiol* **38:** 198–212.

- Lewis, R.J., Brannigan, J.A., Barák, I., and Wilkinson, A.J. (2001) Lessons and questions from the structure of the Spo0A activation domain: response. *Trends Microbiol* **9**: 150–151.
- Lewis, R.J., Scott, D.J., Brannigan, J.A., Ladds, J.C., Cervin, M.A., Spiegelman, G.B., *et al.* (2002) Dimer formation and transcription activation in the sporulation response regulator Spo0A. *J Mol Biol* **316**: 235–245.
- McEvoy, M.M., Hausrath, A.C., Randolph, G.B., Remington, S.J., and Dahlquist, F.W. (1998) Two binding modes reveal flexibility in kinase/response regulator interactions in the bacterial chemotaxis pathway. *Proc Natl Acad Sci USA* **95**: 7333–7338.
- Madhusudan, Zapf, J., Hoch, J.A., Whiteley, J.M., Xuong, N.H., and Varughese, K.I. (1997) A response regulatory protein with the site of phosphorylation blocked by an arginine interaction: crystal structure of Spo0F from *Bacillus subtilis. Biochemistry* **36**: 12739–12745.
- Muchová, K., Lewis, R.J., Brannigan, J.A., Offen, W.A., Brown, D.P., Barák, I., *et al.* (1999) Crystallisation of the regulatory and effector domains of the key sporulation response regulator Spo0A. *Acta Crystallogr* **D55**: 671–676.
- Olmedo, G., Ninfa, E.G., Stock, J., and Youngman, P. (1990) Novel mutations that alter regulation of sporulation in *Bacillus subtilis*: evidence that phosphorylation of regulatory protein Spo0A controls the initiation of sporulation. *J Mol Biol* **215**: 359–372.
- Park, S., Meyer, M., Jones, A.D., Yennawar, H.P., Yennawar, N.H., and Nixon, B.T. (2002) Two-component signalling in the AAA+ ATPase DctD: binding Mg<sup>2+</sup> and BeF3<sup>-</sup> selects between alternate dimeric states of the receiver domain. *FASEB J* 16: 1964–1966.
- Perego, M., Wu, J.-J., Spiegelman, G.B., and Hoch, J.A. (1991) Mutational dissociation of the positive and negative regulatory properties of the Spo0A sporulation transcription factor of *Bacillus subtilis. Gene* **100**: 207–212.
- Saito, K., Ito, E., Hosono, K., Nakamura, K., Imai, K., Iizuka, T., et al. (2003) The uncoupling of oxygen sensing, phosphorylation signalling and transcriptional activation in oxygen sensor FixL and FixJ mutants. *Mol Microbiol* 48: 373–383.
- Schmeisser, F., Brannigan, J.A., Lewis, R.J., Wilkinson, A.J., Youngman, P., and Barák, I. (2000) A new mutation in *spo0A* with intragenic suppressors in the effector domain. *FEMS Microbiol Lett* 185: 123–128.
- Schuck, P. (2000) Size distribution analysis of macromolecules by sedimentation velocity ultracentrifugation and Lamm equation modeling. *Biophys J* 78: 1606–1619.
- Spiegelman, G.B., Van Hoy, B., Perego, M., Day, J., Trach, K., and Hoch, J.A. (1990) Structural alterations in the *Bacillus subtilis* Spo0A regulatory protein which suppresses mutations at several *spo0* loci. *J Bacteriol* **172**: 5011–5019.
- Spiegelman, G.B., Bird, T.H., and Voon, V. (1995) Transcription regulation by the Spo0A protein of *Bacillus subtilis*. In *Two-Component Signal Transduction*. Hoch, J.A., and Silhavy, T.J. (eds). Washington, DC: American Society for Microbiology Press, pp. 159–179.

842 K. Muchová et al.

- Strauch, M.A., Webb, V., Spiegelman, G.B., and Hoch, J.A. (1990) The Spo0A protein of *Bacillus subtilis* is a repressor of the *abrB* gene. *Proc Natl Acad Sci USA* 87: 1801–1805.
- Trach, K., Burbulys, D., Strauch, M.A., Wu, J.-J., Dhillion, N., Jonas, R., *et al.* (1991) Control of the initiation of sporulation in *Bacillus subtilis* by a phosphorelay. *Res Microbiol* **142:** 815–823.
- Tzeng, Y., and Hoch, J.A. (1997) Molecular recognition in signal transduction: the interaction surfaces of the SpoOF response regulator with its cognate phosphorelay proteins revealed by alanine scanning mutagenesis. *J Mol Biol* **272**: 200–212.
- Yanish-Perron, C., Vieira, J., and Messing, J. (1985) Improved M13 phage cloning vectors and host strains: nucleotide sequences of the M13mp18 and pUC19 vectors. *Gene* **33**: 103–119.

Youngman, P. (1990) Use of transposons and integrational

vectors for mutagenesis and construction of gene fusions in *Bacillus* species. In *Molecular Biological Methods for Bacillus*. Harwood, C.R., and Cutting, S.M. (eds). Chichester: John Wiley & Sons, pp. 221–266.

- Zapf, J.W., Hoch, J.A., and Whiteley, J.M. (1996) A phosphotransferase activity of the *Bacillus subtilis* sporulation protein Spo0F that employs phosphoramidate substrates. *Biochemistry* **35:** 2926–2933.
- Zapf, J., Madhusudan, Sen, U., Hoch, J.A., and Varughese, K.I. (2000) A transient interaction between two phosphorelay proteins trapped in a crystal lattice reveals the mechanism of molecular recognition and phosphotransfer in signal transduction. *Structure* **8:** 851–862.
- Zhao, H., Msadek, T., Zapf, J., Madhusudan, Hoch, J.A., and Varughese, K.I. (2002) DNA complex structure of the key transcription factor initiating development in sporulating bacteria. *Structure* **10**: 1041–1050.